ClinicalTrials.gg
TerminatedNCT04585815Updated Jan 9, 2026Results posted

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

A Phase 1/2 interventional study of Sasanlimab Prefilled syringe and Encorafenib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Terminated at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
99th of 136
34 · median 79
Started
2020
with 13 others
Phase 1/2
13 of 158
1 open now
Registered
105th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 99th largest by enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 13 in phase 1/2, and was the 105th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.

Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination.

Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated.

Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.

Read the detailed description

Landscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell lung cancer (NSCLC). The purpose of this study is to learn if the study medicine (sasanlimab, a type of immunotherapy) along with other study medicines is safe and effective in people with non-small cell lung cancer that has spread outside of the lungs. There are currently two sub-studies using different types of medicines. People in the first sub-study will receive sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 4 weeks. Additionally, they will take targeted cancer therapies encorafenib by mouth once a day and binimetinib by mouth twice a day at home.

People in the second sub-study will receive the study medicine sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 3 weeks and will also receive SEA-TGT (an immunotherapy) by infusion every three weeks.

Additionally, they will take axitinib (a targeted therapy) by mouth twice a day at home.

In addition to taking the study drugs, participants in the sub-studies will be asked to visit the clinic for health checks. These include health questions, physical examinations, blood and urine samples, and imaging scans. These assessments help the study doctor and team to monitor the participants' safety and well-being, and to see how their cancer is responding to the treatment. Participants will continue in the study until the cancer is no longer responding to the study medicine.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Non-Small-Cell Lung Carcinoma
  • NSCLC
  • non small cell lung cancer
  • non-small cell lung cancer
  • BRAF mutation
  • BRAF V600e
  • BRAF
  • B-RAF NSCLC
  • lung cancer
  • immunotherapy
  • sasanlimab
  • encorafenib
  • binimetinib
  • axitinib
  • SEA-TGT
  • TIGIT
  • locally advanced
  • metastatic
  • ECOG 0
  • ECOG 1
  • Stage 3B
  • Stage IV
  • previously untreated
  • second-line therapy
  • first-line therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced/ (Stage IIIB-IV) NSCLC.
  • At least one per v1.1 at Screening.
  • Performance Status 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1.
  • Adequate hepatic, renal, and bone marrow function.

Additional Inclusion Criteria for Sub-Study A Phase 1b \&2:

-BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report.

Additional Inclusion Criteria for Sub-Study A Phase 1b only:

-Any for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study A Phase 2 only:

-Previously untreated for locally advanced/metastatic NSCLC

Additional Inclusion Criteria for Sub-Study B Phase 1b only::

-Any line of therapy for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study B Phase 2 only:

  • Previously untreated for locally advanced/metastatic NSCLC (Arms B1 \& B2), or
  • One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including treatment + chemotherapy, and have progressed during or after that therapy.
  • PD-L1 TPS ≥1%

Exclusion criteria

Exclusion Criteria Umbrella Phase 1b \&2:

  • Active or prior disease that might deteriorate when receiving an immunostimulatory agent.
  • Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune-mediated pneumonitis.
  • Active infection requiring systemic therapy.
  • cardiovascular disease.
  • Other within 2 years of first dose, with exceptions.
  • Symptomatic , with exceptions.

Additional Exclusion Criteria for Sub-Study A Phase 1b\&2:

  • EGFR mutation, ALK fusion oncogene, or ROS1 rearrangement.
  • Prior treatment with any BRAF inhibitor or MEK inhibitor.

Additional Exclusion Criteria for Sub-Study A Phase 2 only:

-Prior therapy with , anti-PD-L1, or anti-PD-L2 agents.

Additional Exclusion Criteria for Sub-Study B Phase 1b\&2:

-Documentation of any tumor-driving molecular alteration (eg, BRAF, EGFR, ALK)

Additional Exclusion Criteria for Sub-Study B Phase 2 only:

  • Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.(Arms B1 \& B2)
  • Confirmed progressive disease on 1st or 2nd imaging tumor assessment after initiation of therapy for advanced/ NSCLC.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Sub-Study A

    Sasanlimab will be administered subcutaneously. Encorafenib \& binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.

    Drug: Sasanlimab Prefilled syringe · Drug: Encorafenib · Drug: Binimetinib

  • Experimental
    Sub-Study B

    Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.

    Drug: Sasanlimab · Drug: Axitinib · Drug: SEA-TGT

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)

    DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.

    Time frame: Day 1 up to Day 28 of Cycle 1

  2. Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)

    Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

  3. Phase 1b of Sub-Study B: Percentage of Participants With DLT

    DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.

    Time frame: Day 1 up to Day 21 of Cycle 1

  4. Phase 2 Sub-Study B: Objective Response Rate

    ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)

Secondary outcomes

  1. Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  2. Phase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment

  3. Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0

    Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  4. Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0

    Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  5. Phase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities

    Hematology and clinical chemistry parameters were planned to be assessed.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment

  6. Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR)

    Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)

  7. Phase 1b of Sub-Study A: Objective Response Rate

    Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)

  8. Phase 2 of Sub-Study A: Objective Response Rate

    Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

  9. Phase 2 of Sub-Study A: Duration of Response (DR)

    DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first

  10. Phase 2 of Sub-Study A: Time to Tumor Response (TTR)

    TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

    Time frame: From the date of first dose of study treatment to the date of first documentation of objective response

  11. Phase 2 of Sub-Study A: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first

  12. Phase 2 of Sub-Study A: Overall Survival (OS)

    OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.

    Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date

  13. Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab

    AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose.

    Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)

  14. Phase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab

    Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)

  15. Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab

    Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)

  16. Phase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab

    Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

  17. Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab

    Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)

  18. Phase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab

    Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

  19. Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab

    Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

  20. Phase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab

    Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

  21. Phase 1b of Sub-Study A: Ctrough of Encorafenib

    Time frame: Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days)

  22. Phase 2 of Sub-Study A: Ctrough of Encorafenib

    Time frame: Cycle 5 Day 1 (pre-dose)

  23. Phase 1b of Sub-Study A: Ctrough of Binimetinib

    Time frame: Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days)

  24. Phase 2 of Sub-Study A: Ctrough of Binimetinib

    Time frame: Cycle 5 Day 1 (pre-dose)

  25. Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab

    In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

    Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days)

  26. Phase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab

    Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment

  27. Phase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline

    OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

  28. Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score

    EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact.

    Time frame: Baseline up to end of treatment

  29. Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score

    The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms.

    Time frame: Baseline up to end of treatment

  30. Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  31. Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  32. Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0

    Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 39.3 months; maximum follow-up approximately 39.66 months)

  33. Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0

    Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  34. Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0

    Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  35. Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0

    Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)

  36. Phase 1b of Sub-Study B: Objective Response Rate

    ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months)

  37. Phase 1b of Sub-Study B: Duration of Response (DR)

    DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)

  38. Phase 1b of Sub-Study B: Time to Tumor Response (TTR)

    TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

    Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)

  39. Phase 1b of Sub-Study B: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)

  40. Phase 2 of Sub-Study B: Duration of Response (DR)

    DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)

  41. Phase 2 of Sub-Study B: Time to Tumor Response (TTR)

    TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

    Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)

  42. Phase 2 of Sub-Study B: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)

  43. Phase 2 of Sub-Study B: Overall Survival (OS)

    OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.

    Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months)

  44. Phase 1b of Sub-Study B: Cmax of Sasanlimab

    Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)

  45. Phase 1b of Sub-Study B: Cmax of Axitinib

    Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)

  46. Phase 1b of Sub-Study B: Cmax of SEA-TGT

    Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)

  47. Phase 2 of Sub-Study B: Cmax of Sasanlimab

    Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)

  48. Phase 2 of Sub-Study B: Cmax of Axitinib

    Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)

  49. Phase 2 of Sub-Study B: Cmax of SEA-TGT

    Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)

  50. Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab

    Time frame: Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days)

  51. Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)

  52. Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT

    Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)

  53. Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab

    Time frame: Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days)

  54. Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib

    Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)

  55. Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT

    Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)

  56. Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT

    A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

    Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)

  57. Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT

    Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)

  58. Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue

    ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

    Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)

07

Results

Posted Jun 22, 2023
Limitations and caveats
Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated, and no data was collected and there are no results for this in the record.

Participant flow

Sub-study A (SSA) was planned to be conducted in 2 parts: Phase 1b and Phase 2. Due to a business decision, Phase 2 was not initiated, hence no participants were enrolled for Phase 2 of SSA. Sub-study B (SSB) was conducted in 2 parts: Phase 1b and Phase 2.

Sub-study A- Treatment Phase
Participant flow — Sub-study A- Treatment Phase
MilestonePhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Started4900000
Completed0000000
Not completed4900000
Withdrew: Adverse event1400000
Withdrew: Death0200000
Withdrew: Withdrawal by subject1000000
Withdrew: Global deterioration of health status0100000
Withdrew: Progressive disease0100000
Withdrew: Study terminated by sponsor1100000
Withdrew: Other1000000
Sub-study A- Follow-up Phase
Participant flow — Sub-study A- Follow-up Phase
MilestonePhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Started2500000
Completed1100000
Not completed1400000
Withdrew: Death0100000
Withdrew: Study terminated by sponsor1300000
Sub-study B- Treatment Phase
Participant flow — Sub-study B- Treatment Phase
MilestonePhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Started0036327
Completed0000000
Not completed0036327
Withdrew: Adverse event0000002
Withdrew: Death0001000
Withdrew: Progressive disease0032215
Withdrew: Withdrawal by subject0001010
Withdrew: Global deterioration of health status0001000
Withdrew: Physician decision0001100
Sub-study B- Follow-up Phase
Participant flow — Sub-study B- Follow-up Phase
MilestonePhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Started0023326
Completed0010213
Not completed0013113
Withdrew: Death0013103
Withdrew: Study terminated by sponsor0000010

Outcome measures

PrimaryPhase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)

DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.

Time frame:
Day 1 up to Day 28 of Cycle 1
Reported as:
Number · Percentage of participants
Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)
Percentage of participantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)033.3
PrimaryPhase 2 of Sub-Study A: Durable Objective Response Rate (ORR)

Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

No measurements were reported for this outcome.

PrimaryPhase 1b of Sub-Study B: Percentage of Participants With DLT

DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.

Time frame:
Day 1 up to Day 21 of Cycle 1
Reported as:
Number · Percentage of participants
Phase 1b of Sub-Study B: Percentage of Participants With DLT
Percentage of participantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Phase 1b of Sub-Study B: Percentage of Participants With DLT01
PrimaryPhase 2 Sub-Study B: Objective Response Rate

ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Reported as:
Median · Percentage of participants
Phase 2 Sub-Study B: Objective Response Rate
Percentage of participantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 Sub-Study B: Objective Response Rate33.3 (0.8 to 90.6)0 (0.0 to 84.2)14.3 (0.4 to 57.9)
SecondaryPhase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Grade 110
Grade 202
Grade 334
Grade 402
Grade 501
SecondaryPhase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0

Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Anemia — Grade 0 to 032
Anemia — Grade 0 to 102
Anemia — Grade 0 to 201
Anemia — Grade 0 to 300
Anemia — Grade 0 to 4NANA
Anemia — Grade 1 to 000
Anemia — Grade 1 to 104
Anemia — Grade 1 to 210
Anemia — Grade 1 to 300
Anemia — Grade 1 to 4NANA
Anemia — Grade 2 to 000
Anemia — Grade 2 to 100
Anemia — Grade 2 to 200
Anemia — Grade 2 to 300
Anemia — Grade 2 to 4NANA
Anemia — Grade 3 to 000
Anemia — Grade 3 to 100
Anemia — Grade 3 to 200
Anemia — Grade 3 to 300
Anemia — Grade 3 to 4NANA
Anemia — Grade 4 to 0NANA
Anemia — Grade 4 to 1NANA
Anemia — Grade 4 to 2NANA
Anemia — Grade 4 to 3NANA
Anemia — Grade 4 to 4NANA
Hemoglobin increased — Grade 0 to 048
Hemoglobin increased — Grade 0 to 101
Hemoglobin increased — Grade 0 to 200
Hemoglobin increased — Grade 0 to 300
Hemoglobin increased — Grade 0 to 4NANA
Hemoglobin increased — Grade 1 to 000
Hemoglobin increased — Grade 1 to 100
Hemoglobin increased — Grade 1 to 200
Hemoglobin increased — Grade 1 to 300
Hemoglobin increased — Grade 1 to 4NANA
Hemoglobin increased — Grade 2 to 000
Hemoglobin increased — Grade 2 to 100
Hemoglobin increased — Grade 2 to 200
Hemoglobin increased — Grade 2 to 300
Hemoglobin increased — Grade 2 to 4NANA
Hemoglobin increased — Grade 3 to 000
Hemoglobin increased — Grade 3 to 100
Hemoglobin increased — Grade 3 to 200
Hemoglobin increased — Grade 3 to 300
Hemoglobin increased — Grade 3 to 4NANA
Hemoglobin increased — Grade 4 to 0NANA
Hemoglobin increased — Grade 4 to 1NANA
Hemoglobin increased — Grade 4 to 2NANA
Hemoglobin increased — Grade 4 to 3NANA
Hemoglobin increased — Grade 4 to 4NANA
Leukocytosis — Grade 0 to 049
Leukocytosis — Grade 0 to 1NANA
Leukocytosis — Grade 0 to 2NANA
Leukocytosis — Grade 0 to 300
Leukocytosis — Grade 0 to 4NANA
Leukocytosis — Grade 1 to 0NANA
Leukocytosis — Grade 1 to 1NANA
Leukocytosis — Grade 1 to 2NANA
Leukocytosis — Grade 1 to 3NANA
Leukocytosis — Grade 1 to 4NANA
Leukocytosis — Grade 2 to 0NANA
Leukocytosis — Grade 2 to 1NANA
Leukocytosis — Grade 2 to 2NANA
Leukocytosis — Grade 2 to 3NANA
Leukocytosis — Grade 2 to 4NANA
Leukocytosis — Grade 3 to 000
Leukocytosis — Grade 3 to 1NANA
Leukocytosis — Grade 3 to 2NANA
Leukocytosis — Grade 3 to 300
Leukocytosis — Grade 3 to 4NANA
Leukocytosis — Grade 4 to 0NANA
Leukocytosis — Grade 4 to 1NANA
Leukocytosis — Grade 4 to 2NANA
Leukocytosis — Grade 4 to 3NANA
Leukocytosis — Grade 4 to 4NANA
Lymphocyte count decreased — Grade 0 to 023
Lymphocyte count decreased — Grade 0 to 111
Lymphocyte count decreased — Grade 0 to 212
Lymphocyte count decreased — Grade 0 to 300
Lymphocyte count decreased — Grade 0 to 401
Lymphocyte count decreased — Grade 1 to 000
Lymphocyte count decreased — Grade 1 to 100
Lymphocyte count decreased — Grade 1 to 201
Lymphocyte count decreased — Grade 1 to 300
Lymphocyte count decreased — Grade 1 to 400
Lymphocyte count decreased — Grade 2 to 000
Lymphocyte count decreased — Grade 2 to 100
Lymphocyte count decreased — Grade 2 to 201
Lymphocyte count decreased — Grade 2 to 300
Lymphocyte count decreased — Grade 2 to 400
Lymphocyte count decreased — Grade 3 to 000
Lymphocyte count decreased — Grade 3 to 100
Lymphocyte count decreased — Grade 3 to 200
Lymphocyte count decreased — Grade 3 to 300
Lymphocyte count decreased — Grade 3 to 400
Lymphocyte count decreased — Grade 4 to 000
Lymphocyte count decreased — Grade 4 to 100
Lymphocyte count decreased — Grade 4 to 200
Lymphocyte count decreased — Grade 4 to 300
Lymphocyte count decreased — Grade 4 to 400
Lymphocyte count increased — Grade 0 to 049
Lymphocyte count increased — Grade 0 to 1NANA
Lymphocyte count increased — Grade 0 to 200
Lymphocyte count increased — Grade 0 to 300
Lymphocyte count increased — Grade 0 to 4NANA
Lymphocyte count increased — Grade 1 to 0NANA
Lymphocyte count increased — Grade 1 to 1NANA
Lymphocyte count increased — Grade 1 to 2NANA
Lymphocyte count increased — Grade 1 to 3NANA
Lymphocyte count increased — Grade 1 to 4NANA
Lymphocyte count increased — Grade 2 to 000
Lymphocyte count increased — Grade 2 to 1NANA
Lymphocyte count increased — Grade 2 to 200
Lymphocyte count increased — Grade 2 to 300
Lymphocyte count increased — Grade 2 to 4NANA
Lymphocyte count increased — Grade 3 to 000
Lymphocyte count increased — Grade 3 to 1NANA
Lymphocyte count increased — Grade 3 to 200
Lymphocyte count increased — Grade 3 to 300
Lymphocyte count increased — Grade 3 to 4NANA
Lymphocyte count increased — Grade 4 to 0NANA
Lymphocyte count increased — Grade 4 to 1NANA
Lymphocyte count increased — Grade 4 to 2NANA
Lymphocyte count increased — Grade 4 to 3NANA
Lymphocyte count increased — Grade 4 to 4NANA
Neutrophil count decreased — Grade 0 to 047
Neutrophil count decreased — Grade 0 to 101
Neutrophil count decreased — Grade 0 to 201
Neutrophil count decreased — Grade 0 to 300
Neutrophil count decreased — Grade 0 to 400
Neutrophil count decreased — Grade 1 to 000
Neutrophil count decreased — Grade 1 to 100
Neutrophil count decreased — Grade 1 to 200
Neutrophil count decreased — Grade 1 to 300
Neutrophil count decreased — Grade 1 to 400
Neutrophil count decreased — Grade 2 to 000
Neutrophil count decreased — Grade 2 to 100
Neutrophil count decreased — Grade 2 to 200
Neutrophil count decreased — Grade 2 to 300
Neutrophil count decreased — Grade 2 to 400
Neutrophil count decreased — Grade 3 to 000
Neutrophil count decreased — Grade 3 to 100
Neutrophil count decreased — Grade 3 to 200
Neutrophil count decreased — Grade 3 to 300
Neutrophil count decreased — Grade 3 to 400
Neutrophil count decreased — Grade 4 to 000
Neutrophil count decreased — Grade 4 to 100
Neutrophil count decreased — Grade 4 to 200
Neutrophil count decreased — Grade 4 to 300
Neutrophil count decreased — Grade 4 to 400
Platelet count decreased — Grade 0 to 047
Platelet count decreased — Grade 0 to 101
Platelet count decreased — Grade 0 to 200
Platelet count decreased — Grade 0 to 300
Platelet count decreased — Grade 0 to 400
Platelet count decreased — Grade 1 to 000
Platelet count decreased — Grade 1 to 100
Platelet count decreased — Grade 1 to 201
Platelet count decreased — Grade 1 to 300
Platelet count decreased — Grade 1 to 400
Platelet count decreased — Grade 2 to 000
Platelet count decreased — Grade 2 to 100
Platelet count decreased — Grade 2 to 200
Platelet count decreased — Grade 2 to 300
Platelet count decreased — Grade 2 to 400
Platelet count decreased — Grade 3 to 000
Platelet count decreased — Grade 3 to 100
Platelet count decreased — Grade 3 to 200
Platelet count decreased — Grade 3 to 300
Platelet count decreased — Grade 3 to 400
Platelet count decreased — Grade 4 to 000
Platelet count decreased — Grade 4 to 100
Platelet count decreased — Grade 4 to 200
Platelet count decreased — Grade 4 to 300
Platelet count decreased — Grade 4 to 400
White blood cell decreased — Grade 0 to 038
White blood cell decreased — Grade 0 to 110
White blood cell decreased — Grade 0 to 200
White blood cell decreased — Grade 0 to 300
White blood cell decreased — Grade 0 to 400
White blood cell decreased — Grade 1 to 000
White blood cell decreased — Grade 1 to 100
White blood cell decreased — Grade 1 to 200
White blood cell decreased — Grade 1 to 3000
White blood cell decreased — Grade 1 to 400
White blood cell decreased — Grade 2 to 000
White blood cell decreased — Grade 2 to 100
White blood cell decreased — Grade 2 to 201
White blood cell decreased — Grade 2 to 300
White blood cell decreased — Grade 2 to 400
White blood cell decreased — Grade 3 to 000
White blood cell decreased — Grade 3 to 100
White blood cell decreased — Grade 3 to 200
White blood cell decreased — Grade 3 to 300
White blood cell decreased — Grade 3 to 400
White blood cell decreased — Grade 4 to 000
White blood cell decreased — Grade 4 to 100
White blood cell decreased — Grade 4 to 200
White blood cell decreased — Grade 4 to 300
White blood cell decreased — Grade 4 to 400
SecondaryPhase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0

Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Alanine aminotransferase increased — Grade 0 to 022
Alanine aminotransferase increased — Grade 0 to 122
Alanine aminotransferase increased — Grade 0 to 202
Alanine aminotransferase increased — Grade 0 to 303
Alanine aminotransferase increased — Grade 0 to 400
Alanine aminotransferase increased — Grade 1 to 000
Alanine aminotransferase increased — Grade 1 to 100
Alanine aminotransferase increased — Grade 1 to 200
Alanine aminotransferase increased — Grade 1 to 300
Alanine aminotransferase increased — Grade 1 to 400
Alanine aminotransferase increased — Grade 2 to 000
Alanine aminotransferase increased — Grade 2 to 100
Alanine aminotransferase increased — Grade 2 to 200
Alanine aminotransferase increased — Grade 2 to 300
Alanine aminotransferase increased — Grade 2 to 400
Alanine aminotransferase increased — Grade 3 to 000
Alanine aminotransferase increased — Grade 3 to 100
Alanine aminotransferase increased — Grade 3 to 200
Alanine aminotransferase increased — Grade 3 to 300
Alanine aminotransferase increased — Grade 3 to 400
Alanine aminotransferase increased — Grade 4 to 000
Alanine aminotransferase increased — Grade 4 to 100
Alanine aminotransferase increased — Grade 4 to 200
Alanine aminotransferase increased — Grade 4 to 300
Alanine aminotransferase increased — Grade 4 to 400
Alkaline phosphatase increased — Grade 0 to 013
Alkaline phosphatase increased — Grade 0 to 102
Alkaline phosphatase increased — Grade 0 to 201
Alkaline phosphatase increased — Grade 0 to 300
Alkaline phosphatase increased — Grade 0 to 400
Alkaline phosphatase increased — Grade 1 to 022
Alkaline phosphatase increased — Grade 1 to 100
Alkaline phosphatase increased — Grade 1 to 210
Alkaline phosphatase increased — Grade 1 to 300
Alkaline phosphatase increased — Grade 1 to 400
Alkaline phosphatase increased — Grade 2 to 000
Alkaline phosphatase increased — Grade 2 to 100
Alkaline phosphatase increased — Grade 2 to 200
Alkaline phosphatase increased — Grade 2 to 300
Alkaline phosphatase increased — Grade 2 to 400
Alkaline phosphatase increased — Grade 3 to 001
Alkaline phosphatase increased — Grade 3 to 100
Alkaline phosphatase increased — Grade 3 to 200
Alkaline phosphatase increased — Grade 3 to 300
Alkaline phosphatase increased — Grade 3 to 400
Alkaline phosphatase increased — Grade 4 to 000
Alkaline phosphatase increased — Grade 4 to 100
Alkaline phosphatase increased — Grade 4 to 200
Alkaline phosphatase increased — Grade 4 to 300
Alkaline phosphatase increased — Grade 4 to 400
Aspartate aminotransferase increased — Grade 0 to 022
Aspartate aminotransferase increased — Grade 0 to 124
Aspartate aminotransferase increased — Grade 0 to 201
Aspartate aminotransferase increased — Grade 0 to 301
Aspartate aminotransferase increased — Grade 0 to 400
Aspartate aminotransferase increased — Grade 1 to 000
Aspartate aminotransferase increased — Grade 1 to 100
Aspartate aminotransferase increased — Grade 1 to 201
Aspartate aminotransferase increased — Grade 1 to 300
Aspartate aminotransferase increased — Grade 1 to 400
Aspartate aminotransferase increased — Grade 2 to 000
Aspartate aminotransferase increased — Grade 2 to 100
Aspartate aminotransferase increased — Grade 2 to 200
Aspartate aminotransferase increased — Grade 2 to 300
Aspartate aminotransferase increased — Grade 2 to 400
Aspartate aminotransferase increased — Grade 3 to 000
Aspartate aminotransferase increased — Grade 3 to 100
Aspartate aminotransferase increased — Grade 3 to 200
Aspartate aminotransferase increased — Grade 3 to 300
Aspartate aminotransferase increased — Grade 3 to 400
Aspartate aminotransferase increased — Grade 4 to 000
Aspartate aminotransferase increased — Grade 4 to 100
Aspartate aminotransferase increased — Grade 4 to 200
Aspartate aminotransferase increased — Grade 4 to 300
Aspartate aminotransferase increased — Grade 4 to 400
Blood bilirubin increased — Grade 0 to 048
Blood bilirubin increased — Grade 0 to 100
Blood bilirubin increased — Grade 0 to 200
Blood bilirubin increased — Grade 0 to 301
Blood bilirubin increased — Grade 0 to 400
Blood bilirubin increased — Grade 1 to 000
Blood bilirubin increased — Grade 1 to 100
Blood bilirubin increased — Grade 1 to 200
Blood bilirubin increased — Grade 1 to 300
Blood bilirubin increased — Grade 1 to 400
Blood bilirubin increased — Grade 2 to 000
Blood bilirubin increased — Grade 2 to 100
Blood bilirubin increased — Grade 2 to 200
Blood bilirubin increased — Grade 2 to 300
Blood bilirubin increased — Grade 2 to 400
Blood bilirubin increased — Grade 3 to 000
Blood bilirubin increased — Grade 3 to 100
Blood bilirubin increased — Grade 3 to 200
Blood bilirubin increased — Grade 3 to 300
Blood bilirubin increased — Grade 3 to 400
Blood bilirubin increased — Grade 4 to 000
Blood bilirubin increased — Grade 4 to 100
Blood bilirubin increased — Grade 4 to 200
Blood bilirubin increased — Grade 4 to 300
Blood bilirubin increased — Grade 4 to 400
CPK increased — Grade 0 to 024
CPK increased — Grade 0 to 121
CPK increased — Grade 0 to 202
CPK increased — Grade 0 to 301
CPK increased — Grade 0 to 401
CPK increased — Grade 1 to 000
CPK increased — Grade 1 to 100
CPK increased — Grade 1 to 200
CPK increased — Grade 1 to 300
CPK increased — Grade 1 to 400
CPK increased — Grade 2 to 000
CPK increased — Grade 2 to 100
CPK increased — Grade 2 to 200
CPK increased — Grade 2 to 300
CPK increased — Grade 2 to 400
CPK increased — Grade 3 to 000
CPK increased — Grade 3 to 100
CPK increased — Grade 3 to 200
CPK increased — Grade 3 to 300
CPK increased — Grade 3 to 400
CPK increased — Grade 4 to 000
CPK increased — Grade 4 to 100
CPK increased — Grade 4 to 200
CPK increased — Grade 4 to 300
CPK increased — Grade 4 to 400
Chronic kidney disease — Grade 0 to 013
Chronic kidney disease — Grade 0 to 101
Chronic kidney disease — Grade 0 to 223
Chronic kidney disease — Grade 0 to 300
Chronic kidney disease — Grade 0 to 400
Chronic kidney disease — Grade 1 to 000
Chronic kidney disease — Grade 1 to 111
Chronic kidney disease — Grade 1 to 200
Chronic kidney disease — Grade 1 to 300
Chronic kidney disease — Grade 1 to 400
Chronic kidney disease — Grade 2 to 000
Chronic kidney disease — Grade 2 to 100
Chronic kidney disease — Grade 2 to 201
Chronic kidney disease — Grade 2 to 300
Chronic kidney disease — Grade 2 to 400
Chronic kidney disease — Grade 3 to 000
Chronic kidney disease — Grade 3 to 100
Chronic kidney disease — Grade 3 to 200
Chronic kidney disease — Grade 3 to 300
Chronic kidney disease — Grade 3 to 400
Chronic kidney disease — Grade 4 to 000
Chronic kidney disease — Grade 4 to 100
Chronic kidney disease — Grade 4 to 200
Chronic kidney disease — Grade 4 to 300
Chronic kidney disease — Grade 4 to 400
Creatinine increased — Grade 0 to 016
Creatinine increased — Grade 0 to 122
Creatinine increased — Grade 0 to 211
Creatinine increased — Grade 0 to 300
Creatinine increased — Grade 0 to 400
Creatinine increased — Grade 1 to 000
Creatinine increased — Grade 1 to 100
Creatinine increased — Grade 1 to 200
Creatinine increased — Grade 1 to 300
Creatinine increased — Grade 1 to 400
Creatinine increased — Grade 2 to 000
Creatinine increased — Grade 2 to 100
Creatinine increased — Grade 2 to 200
Creatinine increased — Grade 2 to 300
Creatinine increased — Grade 2 to 400
Creatinine increased — Grade 3 to 000
Creatinine increased — Grade 3 to 100
Creatinine increased — Grade 3 to 200
Creatinine increased — Grade 3 to 300
Creatinine increased — Grade 3 to 400
Creatinine increased — Grade 4 to 000
Creatinine increased — Grade 4 to 100
Creatinine increased — Grade 4 to 200
Creatinine increased — Grade 4 to 300
Creatinine increased — Grade 4 to 400
Hypercalcemia — Grade 0 to 034
Hypercalcemia — Grade 0 to 115
Hypercalcemia — Grade 0 to 200
Hypercalcemia — Grade 0 to 300
Hypercalcemia — Grade 0 to 400
Hypercalcemia — Grade 1 to 000
Hypercalcemia — Grade 1 to 100
Hypercalcemia — Grade 1 to 200
Hypercalcemia — Grade 1 to 300
Hypercalcemia — Grade 1 to 400
Hypercalcemia — Grade 2 to 000
Hypercalcemia — Grade 2 to 100
Hypercalcemia — Grade 2 to 200
Hypercalcemia — Grade 2 to 300
Hypercalcemia — Grade 2 to 400
Hypercalcemia — Grade 3 to 000
Hypercalcemia — Grade 3 to 100
Hypercalcemia — Grade 3 to 200
Hypercalcemia — Grade 3 to 300
Hypercalcemia — Grade 3 to 400
Hypercalcemia — Grade 4 to 000
Hypercalcemia — Grade 4 to 100
Hypercalcemia — Grade 4 to 200
Hypercalcemia — Grade 4 to 300
Hypercalcemia — Grade 4 to 400
Hyperkalemia — Grade 0 to 048
Hyperkalemia — Grade 0 to 101
Hyperkalemia — Grade 0 to 200
Hyperkalemia — Grade 0 to 300
Hyperkalemia — Grade 0 to 400
Hyperkalemia — Grade 1 to 000
Hyperkalemia — Grade 1 to 100
Hyperkalemia — Grade 1 to 200
Hyperkalemia — Grade 1 to 300
Hyperkalemia — Grade 1 to 400
Hyperkalemia — Grade 2 to 000
Hyperkalemia — Grade 2 to 100
Hyperkalemia — Grade 2 to 200
Hyperkalemia — Grade 2 to 300
Hyperkalemia — Grade 2 to 400
Hyperkalemia — Grade 3 to 000
Hyperkalemia — Grade 3 to 100
Hyperkalemia — Grade 3 to 200
Hyperkalemia — Grade 3 to 300
Hyperkalemia — Grade 3 to 400
Hyperkalemia — Grade 4 to 000
Hyperkalemia — Grade 4 to 100
Hyperkalemia — Grade 4 to 200
Hyperkalemia — Grade 4 to 300
Hyperkalemia — Grade 4 to 400
Hypermagnesemia — Grade 0 to 048
Hypermagnesemia — Grade 0 to 101
Hypermagnesemia — Grade 0 to 2NANA
Hypermagnesemia — Grade 0 to 300
Hypermagnesemia — Grade 0 to 400
Hypermagnesemia — Grade 1 to 000
Hypermagnesemia — Grade 1 to 100
Hypermagnesemia — Grade 1 to 2NANA
Hypermagnesemia — Grade 1 to 300
Hypermagnesemia — Grade 1 to 400
Hypermagnesemia — Grade 2 to 0NANA
Hypermagnesemia — Grade 2 to 1NANA
Hypermagnesemia — Grade 2 to 2NANA
Hypermagnesemia — Grade 2 to 3NANA
Hypermagnesemia — Grade 2 to 4NANA
Hypermagnesemia — Grade 3 to 000
Hypermagnesemia — Grade 3 to 100
Hypermagnesemia — Grade 3 to 2NANA
Hypermagnesemia — Grade 3 to 300
Hypermagnesemia — Grade 3 to 400
Hypermagnesemia — Grade 4 to 000
Hypermagnesemia — Grade 4 to 100
Hypermagnesemia — Grade 4 to 2NANA
Hypermagnesemia — Grade 4 to 300
Hypermagnesemia — Grade 4 to 400
Hypernatremia — Grade 0 to 048
Hypernatremia — Grade 0 to 101
Hypernatremia — Grade 0 to 200
Hypernatremia — Grade 0 to 300
Hypernatremia — Grade 0 to 400
Hypernatremia — Grade 1 to 000
Hypernatremia — Grade 1 to 100
Hypernatremia — Grade 1 to 200
Hypernatremia — Grade 1 to 300
Hypernatremia — Grade 1 to 400
Hypernatremia — Grade 2 to 000
Hypernatremia — Grade 2 to 100
Hypernatremia — Grade 2 to 200
Hypernatremia — Grade 2 to 300
Hypernatremia — Grade 2 to 400
Hypernatremia — Grade 3 to 000
Hypernatremia — Grade 3 to 100
Hypernatremia — Grade 3 to 200
Hypernatremia — Grade 3 to 300
Hypernatremia — Grade 3 to 400
Hypernatremia — Grade 4 to 000
Hypernatremia — Grade 4 to 100
Hypernatremia — Grade 4 to 200
Hypernatremia — Grade 4 to 300
Hypernatremia — Grade 4 to 400
Hypoalbuminemia — Grade 0 to 023
Hypoalbuminemia — Grade 0 to 113
Hypoalbuminemia — Grade 0 to 201
Hypoalbuminemia — Grade 0 to 310
Hypoalbuminemia — Grade 0 to 4NANA
Hypoalbuminemia — Grade 1 to 000
Hypoalbuminemia — Grade 1 to 101
Hypoalbuminemia — Grade 1 to 201
Hypoalbuminemia — Grade 1 to 300
Hypoalbuminemia — Grade 1 to 4NANA
Hypoalbuminemia — Grade 2 to 000
Hypoalbuminemia — Grade 2 to 100
Hypoalbuminemia — Grade 2 to 200
Hypoalbuminemia — Grade 2 to 300
Hypoalbuminemia — Grade 2 to 4NANA
Hypoalbuminemia — Grade 3 to 000
Hypoalbuminemia — Grade 3 to 100
Hypoalbuminemia — Grade 3 to 200
Hypoalbuminemia — Grade 3 to 300
Hypoalbuminemia — Grade 3 to 4NANA
Hypoalbuminemia — Grade 4 to 0NANA
Hypoalbuminemia — Grade 4 to 1NANA
Hypoalbuminemia — Grade 4 to 2NANA
Hypoalbuminemia — Grade 4 to 3NANA
Hypoalbuminemia — Grade 4 to 4NANA
Hypocalcemia — Grade 0 to 047
Hypocalcemia — Grade 0 to 102
Hypocalcemia — Grade 0 to 200
Hypocalcemia — Grade 0 to 300
Hypocalcemia — Grade 0 to 400
Hypocalcemia — Grade 1 to 000
Hypocalcemia — Grade 1 to 100
Hypocalcemia — Grade 1 to 200
Hypocalcemia — Grade 1 to 300
Hypocalcemia — Grade 1 to 400
Hypocalcemia — Grade 2 to 000
Hypocalcemia — Grade 2 to 100
Hypocalcemia — Grade 2 to 200
Hypocalcemia — Grade 2 to 300
Hypocalcemia — Grade 2 to 400
Hypocalcemia — Grade 3 to 000
Hypocalcemia — Grade 3 to 100
Hypocalcemia — Grade 3 to 200
Hypocalcemia — Grade 3 to 300
Hypocalcemia — Grade 3 to 400
Hypocalcemia — Grade 4 to 000
Hypocalcemia — Grade 4 to 100
Hypocalcemia — Grade 4 to 200
Hypocalcemia — Grade 4 to 300
Hypocalcemia — Grade 4 to 400
Hypoglycemia — Grade 0 to 047
Hypoglycemia — Grade 0 to 101
Hypoglycemia — Grade 0 to 200
Hypoglycemia — Grade 0 to 300
Hypoglycemia — Grade 0 to 400
Hypoglycemia — Grade 1 to 001
Hypoglycemia — Grade 1 to 100
Hypoglycemia — Grade 1 to 200
Hypoglycemia — Grade 1 to 300
Hypoglycemia — Grade 1 to 400
Hypoglycemia — Grade 2 to 000
Hypoglycemia — Grade 2 to 100
Hypoglycemia — Grade 2 to 200
Hypoglycemia — Grade 2 to 300
Hypoglycemia — Grade 2 to 400
Hypoglycemia — Grade 3 to 000
Hypoglycemia — Grade 3 to 100
Hypoglycemia — Grade 3 to 200
Hypoglycemia — Grade 3 to 300
Hypoglycemia — Grade 3 to 400
Hypoglycemia — Grade 4 to 000
Hypoglycemia — Grade 4 to 100
Hypoglycemia — Grade 4 to 200
Hypoglycemia — Grade 4 to 300
Hypoglycemia — Grade 4 to 400
Hypokalemia — Grade 0 to 047
Hypokalemia — Grade 0 to 1NANA
Hypokalemia — Grade 0 to 201
Hypokalemia — Grade 0 to 301
Hypokalemia — Grade 0 to 400
Hypokalemia — Grade 1 to 0NANA
Hypokalemia — Grade 1 to 1NANA
Hypokalemia — Grade 1 to 2NANA
Hypokalemia — Grade 1 to 3NANA
Hypokalemia — Grade 1 to 4NANA
Hypokalemia — Grade 2 to 000
Hypokalemia — Grade 2 to 1NANA
Hypokalemia — Grade 2 to 200
Hypokalemia — Grade 2 to 300
Hypokalemia — Grade 2 to 400
Hypokalemia — Grade 3 to 000
Hypokalemia — Grade 3 to 1NANA
Hypokalemia — Grade 3 to 200
Hypokalemia — Grade 3 to 300
Hypokalemia — Grade 3 to 400
Hypokalemia — Grade 4 to 000
Hypokalemia — Grade 4 to 1NANA
Hypokalemia — Grade 4 to 200
Hypokalemia — Grade 4 to 300
Hypokalemia — Grade 4 to 400
Hypomagnesemia — Grade 0 to 048
Hypomagnesemia — Grade 0 to 101
Hypomagnesemia — Grade 0 to 200
Hypomagnesemia — Grade 0 to 300
Hypomagnesemia — Grade 0 to 400
Hypomagnesemia — Grade 1 to 000
Hypomagnesemia — Grade 1 to 100
Hypomagnesemia — Grade 1 to 200
Hypomagnesemia — Grade 1 to 300
Hypomagnesemia — Grade 1 to 400
Hypomagnesemia — Grade 2 to 000
Hypomagnesemia — Grade 2 to 100
Hypomagnesemia — Grade 2 to 200
Hypomagnesemia — Grade 2 to 300
Hypomagnesemia — Grade 2 to 400
Hypomagnesemia — Grade 3 to 000
Hypomagnesemia — Grade 3 to 100
Hypomagnesemia — Grade 3 to 200
Hypomagnesemia — Grade 3 to 300
Hypomagnesemia — Grade 3 to 400
Hypomagnesemia — Grade 4 to 000
Hypomagnesemia — Grade 4 to 100
Hypomagnesemia — Grade 4 to 200
Hypomagnesemia — Grade 4 to 300
Hypomagnesemia — Grade 4 to 400
Hyponatremia — Grade 0 to 035
Hyponatremia — Grade 0 to 101
Hyponatremia — Grade 0 to 2NANA
Hyponatremia — Grade 0 to 301
Hyponatremia — Grade 0 to 400
Hyponatremia — Grade 1 to 010
Hyponatremia — Grade 1 to 100
Hyponatremia — Grade 1 to 2NANA
Hyponatremia — Grade 1 to 302
Hyponatremia — Grade 1 to 400
Hyponatremia — Grade 2 to 0NANA
Hyponatremia — Grade 2 to 1NANA
Hyponatremia — Grade 2 to 2NANA
Hyponatremia — Grade 2 to 3NANA
Hyponatremia — Grade 2 to 4NANA
Hyponatremia — Grade 3 to 000
Hyponatremia — Grade 3 to 100
Hyponatremia — Grade 3 to 2NANA
Hyponatremia — Grade 3 to 300
Hyponatremia — Grade 3 to 400
Hyponatremia — Grade 4 to 000
Hyponatremia — Grade 4 to 100
Hyponatremia — Grade 4 to 2NANA
Hyponatremia — Grade 4 to 300
Hyponatremia — Grade 4 to 400
Lipase increased — Grade 0 to 015
Lipase increased — Grade 0 to 123
Lipase increased — Grade 0 to 211
Lipase increased — Grade 0 to 300
Lipase increased — Grade 0 to 400
Lipase increased — Grade 1 to 000
Lipase increased — Grade 1 to 100
Lipase increased — Grade 1 to 200
Lipase increased — Grade 1 to 300
Lipase increased — Grade 1 to 400
Lipase increased — Grade 2 to 000
Lipase increased — Grade 2 to 100
Lipase increased — Grade 2 to 200
Lipase increased — Grade 2 to 300
Lipase increased — Grade 2 to 400
Lipase increased — Grade 3 to 000
Lipase increased — Grade 3 to 100
Lipase increased — Grade 3 to 200
Lipase increased — Grade 3 to 300
Lipase increased — Grade 3 to 400
Lipase increased — Grade 4 to 000
Lipase increased — Grade 4 to 100
Lipase increased — Grade 4 to 200
Lipase increased — Grade 4 to 300
Lipase increased — Grade 4 to 400
Serum amylase increased — Grade 0 to 047
Serum amylase increased — Grade 0 to 100
Serum amylase increased — Grade 0 to 200
Serum amylase increased — Grade 0 to 301
Serum amylase increased — Grade 0 to 400
Serum amylase increased — Grade 1 to 000
Serum amylase increased — Grade 1 to 101
Serum amylase increased — Grade 1 to 200
Serum amylase increased — Grade 1 to 300
Serum amylase increased — Grade 1 to 400
Serum amylase increased — Grade 2 to 000
Serum amylase increased — Grade 2 to 100
Serum amylase increased — Grade 2 to 200
Serum amylase increased — Grade 2 to 300
Serum amylase increased — Grade 2 to 400
Serum amylase increased — Grade 3 to 000
Serum amylase increased — Grade 3 to 100
Serum amylase increased — Grade 3 to 200
Serum amylase increased — Grade 3 to 300
Serum amylase increased — Grade 3 to 400
Serum amylase increased — Grade 4 to 000
Serum amylase increased — Grade 4 to 100
Serum amylase increased — Grade 4 to 200
Serum amylase increased — Grade 4 to 300
Serum amylase increased — Grade 4 to 400
SecondaryPhase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities

Hematology and clinical chemistry parameters were planned to be assessed.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Durable Objective Response Rate (ORR)

Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Reported as:
Number · Percentage of Participants
Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR)
Percentage of ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR)25.0 (0.6 to 80.6)44.4 (13.7 to 78.8)
SecondaryPhase 1b of Sub-Study A: Objective Response Rate

Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Reported as:
Number · Percentage of Participants
Phase 1b of Sub-Study A: Objective Response Rate
Percentage of ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Phase 1b of Sub-Study A: Objective Response Rate50.0 (6.8 to 93.2)44.4 (13.7 to 78.8)
SecondaryPhase 2 of Sub-Study A: Objective Response Rate

Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Duration of Response (DR)

DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Time to Tumor Response (TTR)

TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

Time frame:
From the date of first dose of study treatment to the date of first documentation of objective response

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Progression-Free Survival (PFS)

PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Overall Survival (OS)

OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.

Time frame:
From the date of first dose of study treatment to the date of death due to any cause or censoring date

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab

AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose.

Time frame:
Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
Reported as:
Geometric mean · Micrograms*hour per milliliter
Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
Micrograms*hour per milliliterPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab12500 ± 6524850 ± 17
SecondaryPhase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
Time frame:
Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame:
Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Reported as:
Geometric mean · Micrograms per milliliter
Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Micrograms per milliliterPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Cycle 129.49 ± 5545.04 ± 38
Cycle 564.60 ± NA70.90 ± NA
SecondaryPhase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame:
Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame:
Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Reported as:
Median · Hour
Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
HourPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Cycle 1164 (144 to 168)209 (143 to 359)
Cycle 5168 (168 to 168)162 (162 to 162)
SecondaryPhase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame:
Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame:
Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Reported as:
Geometric mean · Microgram per milliliter
Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Microgram per milliliterPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab37.97 ± 2040.24 ± NA
SecondaryPhase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame:
Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Ctrough of Encorafenib
Time frame:
Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study A: Ctrough of Encorafenib
Nanograms per milliliterPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Cycle 1 Day 1NA ± NANA ± NA
Cycle 1 Day 1512.2 ± 17618.5 ± 50
Cycle 2 Day 1—11.1 ± 204
Cycle 5 Day 15.0 ± NA7.8 ± 191
SecondaryPhase 2 of Sub-Study A: Ctrough of Encorafenib
Time frame:
Cycle 5 Day 1 (pre-dose)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Ctrough of Binimetinib
Time frame:
Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study A: Ctrough of Binimetinib
Nanograms per milliliterPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
Cycle 2 Day 119.2 ± NA40.9 ± 98
Cycle 5 Day 1—35.7 ± 67
SecondaryPhase 2 of Sub-Study A: Ctrough of Binimetinib
Time frame:
Cycle 5 Day 1 (pre-dose)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab

In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

Time frame:
Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
ParticipantsPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)
ADA01
NAb00
SecondaryPhase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
Time frame:
Pre-dose on Cycle 1 Day 1 until end of treatment

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline

OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score

EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact.

Time frame:
Baseline up to end of treatment

No measurements were reported for this outcome.

SecondaryPhase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score

The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms.

Time frame:
Baseline up to end of treatment

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
ParticipantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Grade 100
Grade 210
Grade 324
Grade 401
Grade 501
SecondaryPhase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
ParticipantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Grade 1001
Grade 2002
Grade 3222
Grade 4102
Grade 5000
SecondaryPhase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0

Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 39.3 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
ParticipantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Anemia — Grade 0 to 002
Anemia — Grade 0 to 110
Anemia — Grade 0 to 200
Anemia — Grade 0 to 300
Anemia — Grade 0 to 4NANA
Anemia — Grade 1 to 000
Anemia — Grade 1 to 123
Anemia — Grade 1 to 200
Anemia — Grade 1 to 300
Anemia — Grade 1 to 4NANA
Anemia — Grade 2 to 000
Anemia — Grade 2 to 100
Anemia — Grade 2 to 201
Anemia — Grade 2 to 300
Anemia — Grade 2 to 4NANA
Anemia — Grade 3 to 000
Anemia — Grade 3 to 100
Anemia — Grade 3 to 200
Anemia — Grade 3 to 300
Anemia — Grade 3 to 4NANA
Anemia — Grade 4 to 0NANA
Anemia — Grade 4 to 1NANA
Anemia — Grade 4 to 2NANA
Anemia — Grade 4 to 3NANA
Anemia — Grade 4 to 4NANA
Hemoglobin increased — Grade 0 to 036
Hemoglobin increased — Grade 0 to 100
Hemoglobin increased — Grade 0 to 200
Hemoglobin increased — Grade 0 to 300
Hemoglobin increased — Grade 0 to 4NANA
Hemoglobin increased — Grade 1 to 000
Hemoglobin increased — Grade 1 to 100
Hemoglobin increased — Grade 1 to 200
Hemoglobin increased — Grade 1 to 300
Hemoglobin increased — Grade 1 to 4NANA
Hemoglobin increased — Grade 2 to 000
Hemoglobin increased — Grade 2 to 100
Hemoglobin increased — Grade 2 to 200
Hemoglobin increased — Grade 2 to 300
Hemoglobin increased — Grade 2 to 4NANA
Hemoglobin increased — Grade 3 to 000
Hemoglobin increased — Grade 3 to 100
Hemoglobin increased — Grade 3 to 200
Hemoglobin increased — Grade 3 to 300
Hemoglobin increased — Grade 3 to 4NANA
Hemoglobin increased — Grade 4 to 0NANA
Hemoglobin increased — Grade 4 to 1NANA
Hemoglobin increased — Grade 4 to 2NANA
Hemoglobin increased — Grade 4 to 3NANA
Hemoglobin increased — Grade 4 to 4NANA
Leukocytosis — Grade 0 to 036
Leukocytosis — Grade 0 to 1NANA
Leukocytosis — Grade 0 to 2NANA
Leukocytosis — Grade 0 to 300
Leukocytosis — Grade 0 to 4NANA
Leukocytosis — Grade 1 to 0NANA
Leukocytosis — Grade 1 to 1NANA
Leukocytosis — Grade 1 to 2NANA
Leukocytosis — Grade 1 to 3NANA
Leukocytosis — Grade 1 to 4NANA
Leukocytosis — Grade 2 to 0NANA
Leukocytosis — Grade 2 to 1NANA
Leukocytosis — Grade 2 to 2NANA
Leukocytosis — Grade 2 to 3NANA
Leukocytosis — Grade 2 to 4NANA
Leukocytosis — Grade 3 to 000
Leukocytosis — Grade 3 to 1NANA
Leukocytosis — Grade 3 to 2NANA
Leukocytosis — Grade 3 to 300
Leukocytosis — Grade 3 to 4NANA
Leukocytosis — Grade 4 to 0NANA
Leukocytosis — Grade 4 to 1NANA
Leukocytosis — Grade 4 to 2NANA
Leukocytosis — Grade 4 to 3NANA
Leukocytosis — Grade 4 to 4NANA
Lymphocyte count decreased — Grade 0 to 011
Lymphocyte count decreased — Grade 0 to 100
Lymphocyte count decreased — Grade 0 to 201
Lymphocyte count decreased — Grade 0 to 301
Lymphocyte count decreased — Grade 0 to 401
Lymphocyte count decreased — Grade 1 to 000
Lymphocyte count decreased — Grade 1 to 100
Lymphocyte count decreased — Grade 1 to 220
Lymphocyte count decreased — Grade 1 to 300
Lymphocyte count decreased — Grade 1 to 401
Lymphocyte count decreased — Grade 2 to 000
Lymphocyte count decreased — Grade 2 to 100
Lymphocyte count decreased — Grade 2 to 201
Lymphocyte count decreased — Grade 2 to 300
Lymphocyte count decreased — Grade 2 to 400
Lymphocyte count decreased — Grade 3 to 0000
Lymphocyte count decreased — Grade 3 to 100
Lymphocyte count decreased — Grade 3 to 200
Lymphocyte count decreased — Grade 3 to 300
Lymphocyte count decreased — Grade 3 to 400
Lymphocyte count decreased — Grade 4 to 000
Lymphocyte count decreased — Grade 4 to 100
Lymphocyte count decreased — Grade 4 to 200
Lymphocyte count decreased — Grade 4 to 300
Lymphocyte count decreased — Grade 4 to 400
Lymphocyte count increased — Grade 0 to 036
Lymphocyte count increased — Grade 0 to 1NANA
Lymphocyte count increased — Grade 0 to 200
Lymphocyte count increased — Grade 0 to 300
Lymphocyte count increased — Grade 0 to 4NANA
Lymphocyte count increased — Grade 1 to 0NANA
Lymphocyte count increased — Grade 1 to 1NANA
Lymphocyte count increased — Grade 1 to 2NANA
Lymphocyte count increased — Grade 1 to 3NANA
Lymphocyte count increased — Grade 1 to 4NANA
Lymphocyte count increased — Grade 2 to 000
Lymphocyte count increased — Grade 2 to 1NANA
Lymphocyte count increased — Grade 2 to 200
Lymphocyte count increased — Grade 2 to 300
Lymphocyte count increased — Grade 2 to 4NANA
Lymphocyte count increased — Grade 3 to 000
Lymphocyte count increased — Grade 3 to 1NANA
Lymphocyte count increased — Grade 3 to 200
Lymphocyte count increased — Grade 3 to 300
Lymphocyte count increased — Grade 3 to 4NANA
Lymphocyte count increased — Grade 4 to 0NANA
Lymphocyte count increased — Grade 4 to 1NANA
Lymphocyte count increased — Grade 4 to 2NANA
Lymphocyte count increased — Grade 4 to 3NANA
Lymphocyte count increased — Grade 4 to 4NANA
Neutrophil count decreased — Grade 0 to 036
Neutrophil count decreased — Grade 0 to 100
Neutrophil count decreased — Grade 0 to 200
Neutrophil count decreased — Grade 0 to 300
Neutrophil count decreased — Grade 0 to 400
Neutrophil count decreased — Grade 1 to 000
Neutrophil count decreased — Grade 1 to 100
Neutrophil count decreased — Grade 1 to 200
Neutrophil count decreased — Grade 1 to 300
Neutrophil count decreased — Grade 1 to 400
Neutrophil count decreased — Grade 2 to 000
Neutrophil count decreased — Grade 2 to 100
Neutrophil count decreased — Grade 2 to 200
Neutrophil count decreased — Grade 2 to 300
Neutrophil count decreased — Grade 2 to 400
Neutrophil count decreased — Grade 3 to 000
Neutrophil count decreased — Grade 3 to 100
Neutrophil count decreased — Grade 3 to 200
Neutrophil count decreased — Grade 3 to 300
Neutrophil count decreased — Grade 3 to 400
Neutrophil count decreased — Grade 4 to 000
Neutrophil count decreased — Grade 4 to 100
Neutrophil count decreased — Grade 4 to 200
Neutrophil count decreased — Grade 4 to 300
Neutrophil count decreased — Grade 4 to 400
Platelet count decreased — Grade 0 to 025
Platelet count decreased — Grade 0 to 111
Platelet count decreased — Grade 0 to 200
Platelet count decreased — Grade 0 to 300
Platelet count decreased — Grade 0 to 400
Platelet count decreased — Grade 1 to 000
Platelet count decreased — Grade 1 to 100
Platelet count decreased — Grade 1 to 200
Platelet count decreased — Grade 1 to 300
Platelet count decreased — Grade 1 to 400
Platelet count decreased — Grade 2 to 000
Platelet count decreased — Grade 2 to 100
Platelet count decreased — Grade 2 to 200
Platelet count decreased — Grade 2 to 300
Platelet count decreased — Grade 2 to 400
Platelet count decreased — Grade 3 to 000
Platelet count decreased — Grade 3 to 100
Platelet count decreased — Grade 3 to 200
Platelet count decreased — Grade 3 to 300
Platelet count decreased — Grade 3 to 400
Platelet count decreased — Grade 4 to 000
Platelet count decreased — Grade 4 to 100
Platelet count decreased — Grade 4 to 200
Platelet count decreased — Grade 4 to 300
Platelet count decreased — Grade 4 to 400
White blood cell decreased — Grade 0 to 035
White blood cell decreased — Grade 0 to 101
White blood cell decreased — Grade 0 to 200
White blood cell decreased — Grade 0 to 300
White blood cell decreased — Grade 0 to 400
White blood cell decreased — Grade 1 to 000
White blood cell decreased — Grade 1 to 100
White blood cell decreased — Grade 1 to 200
White blood cell decreased — Grade 1 to 300
White blood cell decreased — Grade 1 to 400
White blood cell decreased — Grade 2 to 000
White blood cell decreased — Grade 2 to 100
White blood cell decreased — Grade 2 to 200
White blood cell decreased — Grade 2 to 300
White blood cell decreased — Grade 2 to 400
White blood cell decreased — Grade 3 to 000
White blood cell decreased — Grade 3 to 100
White blood cell decreased — Grade 3 to 200
White blood cell decreased — Grade 3 to 300
White blood cell decreased — Grade 3 to 400
White blood cell decreased — Grade 4 to 000
White blood cell decreased — Grade 4 to 100
White blood cell decreased — Grade 4 to 200
White blood cell decreased — Grade 4 to 300
White blood cell decreased — Grade 4 to 400
SecondaryPhase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0

Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
ParticipantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
ALT increased — Grade 0 to 015
ALT increased — Grade 0 to 120
ALT increased — Grade 0 to 201
ALT increased — Grade 0 to 300
ALT increased — Grade 0 to 400
ALT increased — Grade 1 to 000
ALT increased — Grade 1 to 100
ALT increased — Grade 1 to 200
ALT increased — Grade 1 to 300
ALT increased — Grade 1 to 400
ALT increased — Grade 2 to 000
ALT increased — Grade 2 to 100
ALT increased — Grade 2 to 200
ALT increased — Grade 2 to 300
ALT increased — Grade 2 to 400
ALT increased — Grade 3 to 000
ALT increased — Grade 3 to 100
ALT increased — Grade 3 to 200
ALT increased — Grade 3 to 300
ALT increased — Grade 3 to 400
ALT increased — Grade 4 to 000
ALT increased — Grade 4 to 100
ALT increased — Grade 4 to 200
ALT increased — Grade 4 to 300
ALT increased — Grade 4 to 400
ALP increased — Grade 0 to 024
ALP increased — Grade 0 to 102
ALP increased — Grade 0 to 200
ALP increased — Grade 0 to 300
ALP increased — Grade 0 to 400
ALP increased — Grade 1 to 000
ALP increased — Grade 1 to 100
ALP increased — Grade 1 to 210
ALP increased — Grade 1 to 300
ALP increased — Grade 1 to 400
ALP increased — Grade 2 to 000
ALP increased — Grade 2 to 100
ALP increased — Grade 2 to 200
ALP increased — Grade 2 to 300
ALP increased — Grade 2 to 400
ALP increased — Grade 3 to 000
ALP increased — Grade 3 to 100
ALP increased — Grade 3 to 200
ALP increased — Grade 3 to 300
ALP increased — Grade 3 to 400
ALP increased — Grade 4 to 000
ALP increased — Grade 4 to 100
ALP increased — Grade 4 to 200
ALP increased — Grade 4 to 300
ALP increased — Grade 4 to 400
AST increased — Grade 0 to 005
AST increased — Grade 0 to 110
AST increased — Grade 0 to 200
AST increased — Grade 0 to 301
AST increased — Grade 0 to 400
AST increased — Grade 1 to 010
AST increased — Grade 1 to 110
AST increased — Grade 1 to 200
AST increased — Grade 1 to 300
AST increased — Grade 1 to 400
AST increased — Grade 2 to 000
AST increased — Grade 2 to 100
AST increased — Grade 2 to 200
AST increased — Grade 2 to 300
AST increased — Grade 2 to 400
AST increased — Grade 3 to 000
AST increased — Grade 3 to 100
AST increased — Grade 3 to 200
AST increased — Grade 3 to 300
AST increased — Grade 3 to 400
AST increased — Grade 4 to 000
AST increased — Grade 4 to 100
AST increased — Grade 4 to 200
AST increased — Grade 4 to 300
AST increased — Grade 4 to 400
Blood bilirubin increased — Grade 0 to 036
Blood bilirubin increased — Grade 0 to 100
Blood bilirubin increased — Grade 0 to 200
Blood bilirubin increased — Grade 0 to 300
Blood bilirubin increased — Grade 0 to 400
Blood bilirubin increased — Grade 1 to 000
Blood bilirubin increased — Grade 1 to 100
Blood bilirubin increased — Grade 1 to 200
Blood bilirubin increased — Grade 1 to 300
Blood bilirubin increased — Grade 1 to 400
Blood bilirubin increased — Grade 2 to 000
Blood bilirubin increased — Grade 2 to 100
Blood bilirubin increased — Grade 2 to 200
Blood bilirubin increased — Grade 2 to 300
Blood bilirubin increased — Grade 2 to 400
Blood bilirubin increased — Grade 3 to 000
Blood bilirubin increased — Grade 3 to 100
Blood bilirubin increased — Grade 3 to 200
Blood bilirubin increased — Grade 3 to 300
Blood bilirubin increased — Grade 3 to 400
Blood bilirubin increased — Grade 4 to 000
Blood bilirubin increased — Grade 4 to 100
Blood bilirubin increased — Grade 4 to 200
Blood bilirubin increased — Grade 4 to 300
Blood bilirubin increased — Grade 4 to 400
CPK increased — Grade 0 to 035
CPK increased — Grade 0 to 100
CPK increased — Grade 0 to 200
CPK increased — Grade 0 to 300
CPK increased — Grade 0 to 400
CPK increased — Grade 1 to 001
CPK increased — Grade 1 to 100
CPK increased — Grade 1 to 200
CPK increased — Grade 1 to 300
CPK increased — Grade 1 to 400
CPK increased — Grade 2 to 000
CPK increased — Grade 2 to 100
CPK increased — Grade 2 to 200
CPK increased — Grade 2 to 300
CPK increased — Grade 2 to 400
CPK increased — Grade 3 to 000
CPK increased — Grade 3 to 100
CPK increased — Grade 3 to 200
CPK increased — Grade 3 to 300
CPK increased — Grade 3 to 400
CPK increased — Grade 4 to 000
CPK increased — Grade 4 to 100
CPK increased — Grade 4 to 200
CPK increased — Grade 4 to 300
CPK increased — Grade 4 to 400
Chronic kidney disease — Grade 0 to 010
Chronic kidney disease — Grade 0 to 112
Chronic kidney disease — Grade 0 to 201
Chronic kidney disease — Grade 0 to 300
Chronic kidney disease — Grade 0 to 400
Chronic kidney disease — Grade 1 to 000
Chronic kidney disease — Grade 1 to 100
Chronic kidney disease — Grade 1 to 2001
Chronic kidney disease — Grade 1 to 300
Chronic kidney disease — Grade 1 to 400
Chronic kidney disease — Grade 2 to 000
Chronic kidney disease — Grade 2 to 100
Chronic kidney disease — Grade 2 to 212
Chronic kidney disease — Grade 2 to 300
Chronic kidney disease — Grade 2 to 400
Chronic kidney disease — Grade 3 to 000
Chronic kidney disease — Grade 3 to 100
Chronic kidney disease — Grade 3 to 200
Chronic kidney disease — Grade 3 to 300
Chronic kidney disease — Grade 3 to 400
Chronic kidney disease — Grade 4 to 000
Chronic kidney disease — Grade 4 to 100
Chronic kidney disease — Grade 4 to 200
Chronic kidney disease — Grade 4 to 300
Chronic kidney disease — Grade 4 to 400
Creatinine increased — Grade 0 to 023
Creatinine increased — Grade 0 to 100
Creatinine increased — Grade 0 to 200
Creatinine increased — Grade 0 to 300
Creatinine increased — Grade 0 to 400
Creatinine increased — Grade 1 to 000
Creatinine increased — Grade 1 to 112
Creatinine increased — Grade 1 to 201
Creatinine increased — Grade 1 to 300
Creatinine increased — Grade 1 to 400
Creatinine increased — Grade 2 to 000
Creatinine increased — Grade 2 to 100
Creatinine increased — Grade 2 to 200
Creatinine increased — Grade 2 to 300
Creatinine increased — Grade 2 to 400
Creatinine increased — Grade 3 to 000
Creatinine increased — Grade 3 to 100
Creatinine increased — Grade 3 to 200
Creatinine increased — Grade 3 to 300
Creatinine increased — Grade 3 to 400
Creatinine increased — Grade 4 to 000
Creatinine increased — Grade 4 to 100
Creatinine increased — Grade 4 to 200
Creatinine increased — Grade 4 to 300
Creatinine increased — Grade 4 to 400
Hypercalcemia — Grade 0 to 015
Hypercalcemia — Grade 0 to 121
Hypercalcemia — Grade 0 to 200
Hypercalcemia — Grade 0 to 300
Hypercalcemia — Grade 0 to 400
Hypercalcemia — Grade 1 to 000
Hypercalcemia — Grade 1 to 100
Hypercalcemia — Grade 1 to 200
Hypercalcemia — Grade 1 to 300
Hypercalcemia — Grade 1 to 400
Hypercalcemia — Grade 2 to 000
Hypercalcemia — Grade 2 to 100
Hypercalcemia — Grade 2 to 200
Hypercalcemia — Grade 2 to 300
Hypercalcemia — Grade 2 to 400
Hypercalcemia — Grade 3 to 000
Hypercalcemia — Grade 3 to 100
Hypercalcemia — Grade 3 to 200
Hypercalcemia — Grade 3 to 300
Hypercalcemia — Grade 3 to 400
Hypercalcemia — Grade 4 to 000
Hypercalcemia — Grade 4 to 100
Hypercalcemia — Grade 4 to 200
Hypercalcemia — Grade 4 to 300
Hypercalcemia — Grade 4 to 400
Hyperkalemia — Grade 0 to 025
Hyperkalemia — Grade 0 to 111
Hyperkalemia — Grade 0 to 200
Hyperkalemia — Grade 0 to 300
Hyperkalemia — Grade 0 to 400
Hyperkalemia — Grade 1 to 000
Hyperkalemia — Grade 1 to 100
Hyperkalemia — Grade 1 to 200
Hyperkalemia — Grade 1 to 300
Hyperkalemia — Grade 1 to 400
Hyperkalemia — Grade 2 to 000
Hyperkalemia — Grade 2 to 100
Hyperkalemia — Grade 2 to 200
Hyperkalemia — Grade 2 to 300
Hyperkalemia — Grade 2 to 400
Hyperkalemia — Grade 3 to 000
Hyperkalemia — Grade 3 to 100
Hyperkalemia — Grade 3 to 200
Hyperkalemia — Grade 3 to 300
Hyperkalemia — Grade 3 to 400
Hyperkalemia — Grade 4 to 000
Hyperkalemia — Grade 4 to 100
Hyperkalemia — Grade 4 to 200
Hyperkalemia — Grade 4 to 300
Hyperkalemia — Grade 4 to 400
Hypermagnesemia — Grade 0 to 036
Hypermagnesemia — Grade 0 to 100
Hypermagnesemia — Grade 0 to 2NANA
Hypermagnesemia — Grade 0 to 300
Hypermagnesemia — Grade 0 to 400
Hypermagnesemia — Grade 1 to 000
Hypermagnesemia — Grade 1 to 100
Hypermagnesemia — Grade 1 to 2NANA
Hypermagnesemia — Grade 1 to 300
Hypermagnesemia — Grade 1 to 400
Hypermagnesemia — Grade 2 to 0NANA
Hypermagnesemia — Grade 2 to 1NANA
Hypermagnesemia — Grade 2 to 2NANA
Hypermagnesemia — Grade 2 to 3NANA
Hypermagnesemia — Grade 2 to 4NANA
Hypermagnesemia — Grade 3 to 000
Hypermagnesemia — Grade 3 to 100
Hypermagnesemia — Grade 3 to 2NANA
Hypermagnesemia — Grade 3 to 300
Hypermagnesemia — Grade 3 to 400
Hypermagnesemia — Grade 4 to 000
Hypermagnesemia — Grade 4 to 100
Hypermagnesemia — Grade 4 to 2NANA
Hypermagnesemia — Grade 4 to 300
Hypermagnesemia — Grade 4 to 400
Hypernatremia — Grade 0 to 036
Hypernatremia — Grade 0 to 100
Hypernatremia — Grade 0 to 200
Hypernatremia — Grade 0 to 300
Hypernatremia — Grade 0 to 400
Hypernatremia — Grade 1 to 000
Hypernatremia — Grade 1 to 100
Hypernatremia — Grade 1 to 200
Hypernatremia — Grade 1 to 300
Hypernatremia — Grade 1 to 400
Hypernatremia — Grade 2 to 000
Hypernatremia — Grade 2 to 100
Hypernatremia — Grade 2 to 200
Hypernatremia — Grade 2 to 300
Hypernatremia — Grade 2 to 400
Hypernatremia — Grade 3 to 000
Hypernatremia — Grade 3 to 100
Hypernatremia — Grade 3 to 200
Hypernatremia — Grade 3 to 300
Hypernatremia — Grade 3 to 400
Hypernatremia — Grade 4 to 000
Hypernatremia — Grade 4 to 100
Hypernatremia — Grade 4 to 200
Hypernatremia — Grade 4 to 300
Hypernatremia — Grade 4 to 400
Hypoalbuminemia — Grade 0 to 022
Hypoalbuminemia — Grade 0 to 111
Hypoalbuminemia — Grade 0 to 201
Hypoalbuminemia — Grade 0 to 300
Hypoalbuminemia — Grade 0 to 4NANA
Hypoalbuminemia — Grade 1 to 000
Hypoalbuminemia — Grade 1 to 100
Hypoalbuminemia — Grade 1 to 201
Hypoalbuminemia — Grade 1 to 300
Hypoalbuminemia — Grade 1 to 4NANA
Hypoalbuminemia — Grade 2 to 000
Hypoalbuminemia — Grade 2 to 100
Hypoalbuminemia — Grade 2 to 201
Hypoalbuminemia — Grade 2 to 300
Hypoalbuminemia — Grade 2 to 4NANA
Hypoalbuminemia — Grade 3 to 000
Hypoalbuminemia — Grade 3 to 100
Hypoalbuminemia — Grade 3 to 200
Hypoalbuminemia — Grade 3 to 300
Hypoalbuminemia — Grade 3 to 4NANA
Hypoalbuminemia — Grade 4 to 0NANA
Hypoalbuminemia — Grade 4 to 1NANA
Hypoalbuminemia — Grade 4 to 2NANA
Hypoalbuminemia — Grade 4 to 3NANA
Hypoalbuminemia — Grade 4 to 4NANA
Hypocalcemia — Grade 0 to 036
Hypocalcemia — Grade 0 to 100
Hypocalcemia — Grade 0 to 200
Hypocalcemia — Grade 0 to 300
Hypocalcemia — Grade 0 to 400
Hypocalcemia — Grade 1 to 000
Hypocalcemia — Grade 1 to 100
Hypocalcemia — Grade 1 to 200
Hypocalcemia — Grade 1 to 300
Hypocalcemia — Grade 1 to 400
Hypocalcemia — Grade 2 to 000
Hypocalcemia — Grade 2 to 100
Hypocalcemia — Grade 2 to 200
Hypocalcemia — Grade 2 to 300
Hypocalcemia — Grade 2 to 400
Hypocalcemia — Grade 3 to 000
Hypocalcemia — Grade 3 to 100
Hypocalcemia — Grade 3 to 200
Hypocalcemia — Grade 3 to 300
Hypocalcemia — Grade 3 to 400
Hypocalcemia — Grade 4 to 000
Hypocalcemia — Grade 4 to 100
Hypocalcemia — Grade 4 to 200
Hypocalcemia — Grade 4 to 300
Hypocalcemia — Grade 4 to 400
Hypoglycemia — Grade 0 to 025
Hypoglycemia — Grade 0 to 111
Hypoglycemia — Grade 0 to 200
Hypoglycemia — Grade 0 to 300
Hypoglycemia — Grade 0 to 400
Hypoglycemia — Grade 1 to 000
Hypoglycemia — Grade 1 to 100
Hypoglycemia — Grade 1 to 200
Hypoglycemia — Grade 1 to 300
Hypoglycemia — Grade 1 to 400
Hypoglycemia — Grade 2 to 000
Hypoglycemia — Grade 2 to 100
Hypoglycemia — Grade 2 to 200
Hypoglycemia — Grade 2 to 300
Hypoglycemia — Grade 2 to 400
Hypoglycemia — Grade 3 to 000
Hypoglycemia — Grade 3 to 100
Hypoglycemia — Grade 3 to 200
Hypoglycemia — Grade 3 to 300
Hypoglycemia — Grade 3 to 400
Hypoglycemia — Grade 4 to 000
Hypoglycemia — Grade 4 to 100
Hypoglycemia — Grade 4 to 200
Hypoglycemia — Grade 4 to 300
Hypoglycemia — Grade 4 to 400
Hypokalemia — Grade 0 to 024
Hypokalemia — Grade 0 to 1NANA
Hypokalemia — Grade 0 to 212
Hypokalemia — Grade 0 to 300
Hypokalemia — Grade 0 to 400
Hypokalemia — Grade 1 to 0NANA
Hypokalemia — Grade 1 to 1NANA
Hypokalemia — Grade 1 to 2NANA
Hypokalemia — Grade 1 to 3NANA
Hypokalemia — Grade 1 to 4NANA
Hypokalemia — Grade 2 to 000
Hypokalemia — Grade 2 to 1NANA
Hypokalemia — Grade 2 to 200
Hypokalemia — Grade 2 to 300
Hypokalemia — Grade 2 to 400
Hypokalemia — Grade 3 to 000
Hypokalemia — Grade 3 to 1NANA
Hypokalemia — Grade 3 to 200
Hypokalemia — Grade 3 to 300
Hypokalemia — Grade 3 to 400
Hypokalemia — Grade 4 to 000
Hypokalemia — Grade 4 to 1NANA
Hypokalemia — Grade 4 to 200
Hypokalemia — Grade 4 to 300
Hypokalemia — Grade 4 to 400
Hypomagnesemia — Grade 0 to 015
Hypomagnesemia — Grade 0 to 111
Hypomagnesemia — Grade 0 to 200
Hypomagnesemia — Grade 0 to 300
Hypomagnesemia — Grade 0 to 400
Hypomagnesemia — Grade 1 to 000
Hypomagnesemia — Grade 1 to 100
Hypomagnesemia — Grade 1 to 200
Hypomagnesemia — Grade 1 to 300
Hypomagnesemia — Grade 1 to 400
Hypomagnesemia — Grade 2 to 000
Hypomagnesemia — Grade 2 to 110
Hypomagnesemia — Grade 2 to 200
Hypomagnesemia — Grade 2 to 300
Hypomagnesemia — Grade 2 to 400
Hypomagnesemia — Grade 3 to 000
Hypomagnesemia — Grade 3 to 100
Hypomagnesemia — Grade 3 to 200
Hypomagnesemia — Grade 3 to 300
Hypomagnesemia — Grade 3 to 400
Hypomagnesemia — Grade 4 to 000
Hypomagnesemia — Grade 4 to 100
Hypomagnesemia — Grade 4 to 200
Hypomagnesemia — Grade 4 to 300
Hypomagnesemia — Grade 4 to 400
Hyponatremia — Grade 0 to 024
Hyponatremia — Grade 0 to 112
Hyponatremia — Grade 0 to 2NANA
Hyponatremia — Grade 0 to 300
Hyponatremia — Grade 0 to 400
Hyponatremia — Grade 1 to 000
Hyponatremia — Grade 1 to 100
Hyponatremia — Grade 1 to 2NANA
Hyponatremia — Grade 1 to 300
Hyponatremia — Grade 1 to 400
Hyponatremia — Grade 2 to 0NANA
Hyponatremia — Grade 2 to 1NANA
Hyponatremia — Grade 2 to 2NANA
Hyponatremia — Grade 2 to 3NANA
Hyponatremia — Grade 2 to 4NANA
Hyponatremia — Grade 3 to 000
Hyponatremia — Grade 3 to 100
Hyponatremia — Grade 3 to 2NANA
Hyponatremia — Grade 3 to 300
Hyponatremia — Grade 3 to 400
Hyponatremia — Grade 4 to 000
Hyponatremia — Grade 4 to 100
Hyponatremia — Grade 4 to 2NANA
Hyponatremia — Grade 4 to 300
Hyponatremia — Grade 4 to 400
Lipase increased — Grade 0 to 034
Lipase increased — Grade 0 to 102
Lipase increased — Grade 0 to 200
Lipase increased — Grade 0 to 300
Lipase increased — Grade 0 to 400
Lipase increased — Grade 1 to 000
Lipase increased — Grade 1 to 100
Lipase increased — Grade 1 to 200
Lipase increased — Grade 1 to 300
Lipase increased — Grade 1 to 400
Lipase increased — Grade 2 to 000
Lipase increased — Grade 2 to 100
Lipase increased — Grade 2 to 200
Lipase increased — Grade 2 to 300
Lipase increased — Grade 2 to 400
Lipase increased — Grade 3 to 000
Lipase increased — Grade 3 to 100
Lipase increased — Grade 3 to 200
Lipase increased — Grade 3 to 300
Lipase increased — Grade 3 to 400
Lipase increased — Grade 4 to 000
Lipase increased — Grade 4 to 100
Lipase increased — Grade 4 to 200
Lipase increased — Grade 4 to 300
Lipase increased — Grade 4 to 400
Serum amylase increased — Grade 0 to 034
Serum amylase increased — Grade 0 to 101
Serum amylase increased — Grade 0 to 200
Serum amylase increased — Grade 0 to 300
Serum amylase increased — Grade 0 to 400
Serum amylase increased — Grade 1 to 000
Serum amylase increased — Grade 1 to 100
Serum amylase increased — Grade 1 to 201
Serum amylase increased — Grade 1 to 300
Serum amylase increased — Grade 1 to 400
Serum amylase increased — Grade 2 to 000
Serum amylase increased — Grade 2 to 100
Serum amylase increased — Grade 2 to 200
Serum amylase increased — Grade 2 to 300
Serum amylase increased — Grade 2 to 400
Serum amylase increased — Grade 3 to 000
Serum amylase increased — Grade 3 to 100
Serum amylase increased — Grade 3 to 200
Serum amylase increased — Grade 3 to 300
Serum amylase increased — Grade 3 to 400
Serum amylase increased — Grade 4 to 000
Serum amylase increased — Grade 4 to 100
Serum amylase increased — Grade 4 to 200
Serum amylase increased — Grade 4 to 300
Serum amylase increased — Grade 4 to 400
SecondaryPhase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0

Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0
ParticipantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Anemia — Grade 0 to 0105
Anemia — Grade 0 to 1100
Anemia — Grade 0 to 2000
Anemia — Grade 0 to 3000
Anemia — Grade 0 to 4NANANA
Anemia — Grade 1 to 0001
Anemia — Grade 1 to 1021
Anemia — Grade 1 to 2000
Anemia — Grade 1 to 3000
Anemia — Grade 1 to 4NANANA
Anemia — Grade 2 to 0000
Anemia — Grade 2 to 1000
Anemia — Grade 2 to 2100
Anemia — Grade 2 to 3000
Anemia — Grade 2 to 4NANANA
Anemia — Grade 3 to 0000
Anemia — Grade 3 to 1000
Anemia — Grade 3 to 2000
Anemia — Grade 3 to 3000
Anemia — Grade 3 to 4NANANA
Anemia — Grade 4 to 0NANANA
Anemia — Grade 4 to 1NANANA
Anemia — Grade 4 to 2NANANA
Anemia — Grade 4 to 3NANANA
Anemia — Grade 4 to 4NANANA
Hemoglobin increased — Grade 0 to 0326
Hemoglobin increased — Grade 0 to 1001
Hemoglobin increased — Grade 0 to 2000
Hemoglobin increased — Grade 0 to 3000
Hemoglobin increased — Grade 0 to 4NANANA
Hemoglobin increased — Grade 1 to 0000
Hemoglobin increased — Grade 1 to 1000
Hemoglobin increased — Grade 1 to 2000
Hemoglobin increased — Grade 1 to 3000
Hemoglobin increased — Grade 1 to 4NANANA
Hemoglobin increased — Grade 2 to 0000
Hemoglobin increased — Grade 2 to 1000
Hemoglobin increased — Grade 2 to 2000
Hemoglobin increased — Grade 2 to 3000
Hemoglobin increased — Grade 2 to 4NANANA
Hemoglobin increased — Grade 3 to 0000
Hemoglobin increased — Grade 3 to 1000
Hemoglobin increased — Grade 3 to 2000
Hemoglobin increased — Grade 3 to 3000
Hemoglobin increased — Grade 3 to 4NANANA
Hemoglobin increased — Grade 4 to 0NANANA
Hemoglobin increased — Grade 4 to 1NANANA
Hemoglobin increased — Grade 4 to 2NANANA
Hemoglobin increased — Grade 4 to 3NANANA
Hemoglobin increased — Grade 4 to 4NANANA
Leukocytosis — Grade 0 to 0327
Leukocytosis — Grade 0 to 1NANANA
Leukocytosis — Grade 0 to 2NANANA
Leukocytosis — Grade 0 to 3000
Leukocytosis — Grade 0 to 4NANANA
Leukocytosis — Grade 1 to 0NANANA
Leukocytosis — Grade 1 to 1NANANA
Leukocytosis — Grade 1 to 2NANANA
Leukocytosis — Grade 1 to 3NANANA
Leukocytosis — Grade 1 to 4NANANA
Leukocytosis — Grade 2 to 0NANANA
Leukocytosis — Grade 2 to 1NANANA
Leukocytosis — Grade 2 to 2NANANA
Leukocytosis — Grade 2 to 3NANANA
Leukocytosis — Grade 2 to 4NANANA
Leukocytosis — Grade 3 to 0000
Leukocytosis — Grade 3 to 1NANANA
Leukocytosis — Grade 3 to 2NANANA
Leukocytosis — Grade 3 to 3000
Leukocytosis — Grade 3 to 4NANANA
Leukocytosis — Grade 4 to 0NANANA
Leukocytosis — Grade 4 to 1NANANA
Leukocytosis — Grade 4 to 2NANANA
Leukocytosis — Grade 4 to 3NANANA
Leukocytosis — Grade 4 to 4NANANA
Lymphocyte count decreased — Grade 0 to 0003
Lymphocyte count decreased — Grade 0 to 1000
Lymphocyte count decreased — Grade 0 to 2002
Lymphocyte count decreased — Grade 0 to 3110
Lymphocyte count decreased — Grade 0 to 4000
Lymphocyte count decreased — Grade 1 to 0000
Lymphocyte count decreased — Grade 1 to 1000
Lymphocyte count decreased — Grade 1 to 2010
Lymphocyte count decreased — Grade 1 to 3101
Lymphocyte count decreased — Grade 1 to 4000
Lymphocyte count decreased — Grade 2 to 0000
Lymphocyte count decreased — Grade 2 to 1000
Lymphocyte count decreased — Grade 2 to 2000
Lymphocyte count decreased — Grade 2 to 3000
Lymphocyte count decreased — Grade 2 to 4100
Lymphocyte count decreased — Grade 3 to 0000
Lymphocyte count decreased — Grade 3 to 1000
Lymphocyte count decreased — Grade 3 to 2000
Lymphocyte count decreased — Grade 3 to 3000
Lymphocyte count decreased — Grade 3 to 4001
Lymphocyte count decreased — Grade 4 to 0000
Lymphocyte count decreased — Grade 4 to 1000
Lymphocyte count decreased — Grade 4 to 2000
Lymphocyte count decreased — Grade 4 to 3000
Lymphocyte count decreased — Grade 4 to 4000
Lymphocyte count increased — Grade 0 to 0327
Lymphocyte count increased — Grade 0 to 1NANANA
Lymphocyte count increased — Grade 0 to 2000
Lymphocyte count increased — Grade 0 to 3000
Lymphocyte count increased — Grade 0 to 4NANANA
Lymphocyte count increased — Grade 1 to 0NANANA
Lymphocyte count increased — Grade 1 to 1NANANA
Lymphocyte count increased — Grade 1 to 2NANANA
Lymphocyte count increased — Grade 1 to 3NANANA
Lymphocyte count increased — Grade 1 to 4NANANA
Lymphocyte count increased — Grade 2 to 0000
Lymphocyte count increased — Grade 2 to 1NANANA
Lymphocyte count increased — Grade 2 to 2000
Lymphocyte count increased — Grade 2 to 3000
Lymphocyte count increased — Grade 2 to 4NANANA
Lymphocyte count increased — Grade 3 to 0000
Lymphocyte count increased — Grade 3 to 1NANANA
Lymphocyte count increased — Grade 3 to 2000
Lymphocyte count increased — Grade 3 to 3000
Lymphocyte count increased — Grade 3 to 4NANANA
Lymphocyte count increased — Grade 4 to 0NANANA
Lymphocyte count increased — Grade 4 to 1NANANA
Lymphocyte count increased — Grade 4 to 2NANANA
Lymphocyte count increased — Grade 4 to 3NANANA
Lymphocyte count increased — Grade 4 to 4NANANA
Neutrophil count decrease — Grade 0 to 0227
Neutrophil count decrease — Grade 0 to 1000
Neutrophil count decrease — Grade 0 to 2100
Neutrophil count decrease — Grade 0 to 3000
Neutrophil count decrease — Grade 0 to 4000
Neutrophil count decrease — Grade 1 to 0000
Neutrophil count decrease — Grade 1 to 1000
Neutrophil count decrease — Grade 1 to 2000
Neutrophil count decrease — Grade 1 to 3000
Neutrophil count decrease — Grade 1 to 4000
Neutrophil count decrease — Grade 2 to 0000
Neutrophil count decrease — Grade 2 to 1000
Neutrophil count decrease — Grade 2 to 2000
Neutrophil count decrease — Grade 2 to 3000
Neutrophil count decrease — Grade 2 to 4000
Neutrophil count decrease — Grade 3 to 0000
Neutrophil count decrease — Grade 3 to 1000
Neutrophil count decrease — Grade 3 to 20000
Neutrophil count decrease — Grade 3 to 3000
Neutrophil count decrease — Grade 3 to 4000
Neutrophil count decrease — Grade 4 to 0000
Neutrophil count decrease — Grade 4 to 1000
Neutrophil count decrease — Grade 4 to 2000
Neutrophil count decrease — Grade 4 to 3000
Neutrophil count decrease — Grade 4 to 4000
Platelet count decreased — Grade 0 to 0226
Platelet count decreased — Grade 0 to 1000
Platelet count decreased — Grade 0 to 2101
Platelet count decreased — Grade 0 to 3000
Platelet count decreased — Grade 0 to 4000
Platelet count decreased — Grade 1 to 0000
Platelet count decreased — Grade 1 to 1000
Platelet count decreased — Grade 1 to 2000
Platelet count decreased — Grade 1 to 3000
Platelet count decreased — Grade 1 to 4000
Platelet count decreased — Grade 2 to 0000
Platelet count decreased — Grade 2 to 1000
Platelet count decreased — Grade 2 to 2000
Platelet count decreased — Grade 2 to 3000
Platelet count decreased — Grade 2 to 4000
Platelet count decreased — Grade 3 to 0000
Platelet count decreased — Grade 3 to 1000
Platelet count decreased — Grade 3 to 2000
Platelet count decreased — Grade 3 to 3000
Platelet count decreased — Grade 3 to 4000
Platelet count decreased — Grade 4 to 0000
Platelet count decreased — Grade 4 to 1000
Platelet count decreased — Grade 4 to 2000
Platelet count decreased — Grade 4 to 3000
Platelet count decreased — Grade 4 to 4000
White blood Cell decreased — Grade 0 to 0115
White blood Cell decreased — Grade 0 to 1102
White blood Cell decreased — Grade 0 to 2000
White blood Cell decreased — Grade 0 to 3100
White blood Cell decreased — Grade 0 to 4000
White blood Cell decreased — Grade 1 to 0000
White blood Cell decreased — Grade 1 to 1010
White blood Cell decreased — Grade 1 to 2000
White blood Cell decreased — Grade 1 to 3000
White blood Cell decreased — Grade 1 to 4000
White blood Cell decreased — Grade 2 to 0000
White blood Cell decreased — Grade 2 to 1000
White blood Cell decreased — Grade 2 to 2000
White blood Cell decreased — Grade 2 to 3000
White blood Cell decreased — Grade 2 to 4000
White blood Cell decreased — Grade 3 to 0000
White blood Cell decreased — Grade 3 to 1000
White blood Cell decreased — Grade 3 to 2000
White blood Cell decreased — Grade 3 to 3000
White blood Cell decreased — Grade 3 to 4000
White blood Cell decreased — Grade 4 to 0000
White blood Cell decreased — Grade 4 to 1000
White blood Cell decreased — Grade 4 to 2000
White blood Cell decreased — Grade 4 to 3000
White blood Cell decreased — Grade 4 to 4000
SecondaryPhase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0

Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Reported as:
Count of participants · Participants
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0
ParticipantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
ALT increased — Grade 0 to 0113
ALT increased — Grade 0 to 1103
ALT increased — Grade 0 to 2000
ALT increased — Grade 0 to 3110
ALT increased — Grade 0 to 4001
ALT increased — Grade 1 to 0000
ALT increased — Grade 1 to 1000
ALT increased — Grade 1 to 2000
ALT increased — Grade 1 to 3000
ALT increased — Grade 1 to 4000
ALT increased — Grade 2 to 0000
ALT increased — Grade 2 to 1000
ALT increased — Grade 2 to 2000
ALT increased — Grade 2 to 3000
ALT increased — Grade 2 to 4000
ALT increased — Grade 3 to 0000
ALT increased — Grade 3 to 1000
ALT increased — Grade 3 to 2000
ALT increased — Grade 3 to 3000
ALT increased — Grade 3 to 4000
ALT increased — Grade 4 to 0000
ALT increased — Grade 4 to 1000
ALT increased — Grade 4 to 2000
ALT increased — Grade 4 to 3000
ALT increased — Grade 4 to 4000
ALP increased — Grade 0 to 0013
ALP increased — Grade 0 to 1212
ALP increased — Grade 0 to 2000
ALP increased — Grade 0 to 3000
ALP increased — Grade 0 to 4000
ALP increased — Grade 1 to 0102
ALP increased — Grade 1 to 1000
ALP increased — Grade 1 to 2000
ALP increased — Grade 1 to 3000
ALP increased — Grade 1 to 4000
ALP increased — Grade 2 to 0000
ALP increased — Grade 2 to 1000
ALP increased — Grade 2 to 2000
ALP increased — Grade 2 to 3000
ALP increased — Grade 2 to 4000
ALP increased — Grade 3 to 0000
ALP increased — Grade 3 to 1000
ALP increased — Grade 3 to 2000
ALP increased — Grade 3 to 3000
ALP increased — Grade 3 to 4000
ALP increased — Grade 4 to 0000
ALP increased — Grade 4 to 1000
ALP increased — Grade 4 to 2000
ALP increased — Grade 4 to 3000
ALP increased — Grade 4 to 4000
AST increase — Grade 0 to 0112
AST increase — Grade 0 to 1104
AST increase — Grade 0 to 2000
AST increase — Grade 0 to 3110
AST increase — Grade 0 to 4001
AST increase — Grade 1 to 0000
AST increase — Grade 1 to 1000
AST increase — Grade 1 to 2000
AST increase — Grade 1 to 3000
AST increase — Grade 1 to 4000
AST increase — Grade 2 to 0000
AST increase — Grade 2 to 1000
AST increase — Grade 2 to 2000
AST increase — Grade 2 to 3000
AST increase — Grade 2 to 4000
AST increase — Grade 3 to 0000
AST increase — Grade 3 to 1000
AST increase — Grade 3 to 2000
AST increase — Grade 3 to 3000
AST increase — Grade 3 to 4000
AST increase — Grade 4 to 0000
AST increase — Grade 4 to 1000
AST increase — Grade 4 to 2000
AST increase — Grade 4 to 3000
AST increase — Grade 4 to 4000
Blood bilirubin increased — Grade 0 to 0216
Blood bilirubin increased — Grade 0 to 1110
Blood bilirubin increased — Grade 0 to 2000
Blood bilirubin increased — Grade 0 to 3001
Blood bilirubin increased — Grade 0 to 4000
Blood bilirubin increased — Grade 1 to 0000
Blood bilirubin increased — Grade 1 to 1000
Blood bilirubin increased — Grade 1 to 2000
Blood bilirubin increased — Grade 1 to 3000
Blood bilirubin increased — Grade 1 to 4000
Blood bilirubin increased — Grade 2 to 0000
Blood bilirubin increased — Grade 2 to 1000
Blood bilirubin increased — Grade 2 to 2000
Blood bilirubin increased — Grade 2 to 3000
Blood bilirubin increased — Grade 2 to 4000
Blood bilirubin increased — Grade 3 to 0000
Blood bilirubin increased — Grade 3 to 1000
Blood bilirubin increased — Grade 3 to 2000
Blood bilirubin increased — Grade 3 to 3000
Blood bilirubin increased — Grade 3 to 4000
Blood bilirubin increased — Grade 4 to 0000
Blood bilirubin increased — Grade 4 to 1000
Blood bilirubin increased — Grade 4 to 2000
Blood bilirubin increased — Grade 4 to 3000
Blood bilirubin increased — Grade 4 to 4000
CPK increased — Grade 0 to 0325
CPK increased — Grade 0 to 1000
CPK increased — Grade 0 to 2000
CPK increased — Grade 0 to 3000
CPK increased — Grade 0 to 4000
CPK increased — Grade 1 to 0001
CPK increased — Grade 1 to 1000
CPK increased — Grade 1 to 2000
CPK increased — Grade 1 to 3000
CPK increased — Grade 1 to 4000
CPK increased — Grade 2 to 0000
CPK increased — Grade 2 to 1000
CPK increased — Grade 2 to 2000
CPK increased — Grade 2 to 3000
CPK increased — Grade 2 to 4000
CPK increased — Grade 3 to 0000
CPK increased — Grade 3 to 1000
CPK increased — Grade 3 to 2000
CPK increased — Grade 3 to 3000
CPK increased — Grade 3 to 4000
CPK increased — Grade 4 to 0000
CPK increased — Grade 4 to 1000
CPK increased — Grade 4 to 2000
CPK increased — Grade 4 to 3000
CPK increased — Grade 4 to 4000
Chronic kidney disease — Grade 0 to 0125
Chronic kidney disease — Grade 0 to 1000
Chronic kidney disease — Grade 0 to 2001
Chronic kidney disease — Grade 0 to 3100
Chronic kidney disease — Grade 0 to 4000
Chronic kidney disease — Grade 1 to 0000
Chronic kidney disease — Grade 1 to 1000
Chronic kidney disease — Grade 1 to 2100
Chronic kidney disease — Grade 1 to 3000
Chronic kidney disease — Grade 1 to 4000
Chronic kidney disease — Grade 2 to 0000
Chronic kidney disease — Grade 2 to 1000
Chronic kidney disease — Grade 2 to 2001
Chronic kidney disease — Grade 2 to 3000
Chronic kidney disease — Grade 2 to 4000
Chronic kidney disease — Grade 3 to 0000
Chronic kidney disease — Grade 3 to 1000
Chronic kidney disease — Grade 3 to 2000
Chronic kidney disease — Grade 3 to 3000
Chronic kidney disease — Grade 3 to 4000
Chronic kidney disease — Grade 4 to 0000
Chronic kidney disease — Grade 4 to 1000
Chronic kidney disease — Grade 4 to 2000
Chronic kidney disease — Grade 4 to 3000
Chronic kidney disease — Grade 4 to 40000
Creatinine increased — Grade 0 to 0125
Creatinine increased — Grade 0 to 1001
Creatinine increased — Grade 0 to 2000
Creatinine increased — Grade 0 to 3100
Creatinine increased — Grade 0 to 4000
Creatinine increased — Grade 1 to 0000
Creatinine increased — Grade 1 to 1101
Creatinine increased — Grade 1 to 2000
Creatinine increased — Grade 1 to 3000
Creatinine increased — Grade 1 to 4000
Creatinine increased — Grade 2 to 0000
Creatinine increased — Grade 2 to 1000
Creatinine increased — Grade 2 to 2000
Creatinine increased — Grade 2 to 3000
Creatinine increased — Grade 2 to 4000
Creatinine increased — Grade 3 to 0000
Creatinine increased — Grade 3 to 1000
Creatinine increased — Grade 3 to 2000
Creatinine increased — Grade 3 to 3000
Creatinine increased — Grade 3 to 4000
Creatinine increased — Grade 4 to 0000
Creatinine increased — Grade 4 to 1000
Creatinine increased — Grade 4 to 2000
Creatinine increased — Grade 4 to 3000
Creatinine increased — Grade 4 to 4000
Hypercalcemia — Grade 0 to 0227
Hypercalcemia — Grade 0 to 1100
Hypercalcemia — Grade 0 to 2000
Hypercalcemia — Grade 0 to 3000
Hypercalcemia — Grade 0 to 4000
Hypercalcemia — Grade 1 to 0000
Hypercalcemia — Grade 1 to 1000
Hypercalcemia — Grade 1 to 2000
Hypercalcemia — Grade 1 to 3000
Hypercalcemia — Grade 1 to 4000
Hypercalcemia — Grade 2 to 0000
Hypercalcemia — Grade 2 to 1000
Hypercalcemia — Grade 2 to 2000
Hypercalcemia — Grade 2 to 3000
Hypercalcemia — Grade 2 to 4000
Hypercalcemia — Grade 3 to 0000
Hypercalcemia — Grade 3 to 1000
Hypercalcemia — Grade 3 to 2000
Hypercalcemia — Grade 3 to 3000
Hypercalcemia — Grade 3 to 4000
Hypercalcemia — Grade 4 to 0000
Hypercalcemia — Grade 4 to 1000
Hypercalcemia — Grade 4 to 2000
Hypercalcemia — Grade 4 to 30000
Hypercalcemia — Grade 4 to 4000
Hyperkalemia — Grade 0 to 0216
Hyperkalemia — Grade 0 to 1011
Hyperkalemia — Grade 0 to 2100
Hyperkalemia — Grade 0 to 3000
Hyperkalemia — Grade 0 to 4000
Hyperkalemia — Grade 1 to 0000
Hyperkalemia — Grade 1 to 1000
Hyperkalemia — Grade 1 to 2000
Hyperkalemia — Grade 1 to 3000
Hyperkalemia — Grade 1 to 4000
Hyperkalemia — Grade 2 to 0000
Hyperkalemia — Grade 2 to 1000
Hyperkalemia — Grade 2 to 2000
Hyperkalemia — Grade 2 to 3000
Hyperkalemia — Grade 2 to 4000
Hyperkalemia — Grade 3 to 0000
Hyperkalemia — Grade 3 to 1000
Hyperkalemia — Grade 3 to 2000
Hyperkalemia — Grade 3 to 3000
Hyperkalemia — Grade 3 to 4000
Hyperkalemia — Grade 4 to 0000
Hyperkalemia — Grade 4 to 1000
Hyperkalemia — Grade 4 to 2000
Hyperkalemia — Grade 4 to 3000
Hyperkalemia — Grade 4 to 4000
Hypermagnesemia — Grade 0 to 0326
Hypermagnesemia — Grade 0 to 1001
Hypermagnesemia — Grade 0 to 2NANANA
Hypermagnesemia — Grade 0 to 3000
Hypermagnesemia — Grade 0 to 4000
Hypermagnesemia — Grade 1 to 0000
Hypermagnesemia — Grade 1 to 1000
Hypermagnesemia — Grade 1 to 2NANANA
Hypermagnesemia — Grade 1 to 3000
Hypermagnesemia — Grade 1 to 4000
Hypermagnesemia — Grade 2 to 0NANANA
Hypermagnesemia — Grade 2 to 1NANANA
Hypermagnesemia — Grade 2 to 2NANANA
Hypermagnesemia — Grade 2 to 3NANANA
Hypermagnesemia — Grade 2 to 4NANANA
Hypermagnesemia — Grade 3 to 0000
Hypermagnesemia — Grade 3 to 1000
Hypermagnesemia — Grade 3 to 2NANANA
Hypermagnesemia — Grade 3 to 3000
Hypermagnesemia — Grade 3 to 4000
Hypermagnesemia — Grade 4 to 0000
Hypermagnesemia — Grade 4 to 1000
Hypermagnesemia — Grade 4 to 2NANANA
Hypermagnesemia — Grade 4 to 3000
Hypermagnesemia — Grade 4 to 4000
Hypernatremia — Grade 0 to 0326
Hypernatremia — Grade 0 to 1001
Hypernatremia — Grade 0 to 2000
Hypernatremia — Grade 0 to 3000
Hypernatremia — Grade 0 to 4000
Hypernatremia — Grade 1 to 0000
Hypernatremia — Grade 1 to 1000
Hypernatremia — Grade 1 to 2000
Hypernatremia — Grade 1 to 3000
Hypernatremia — Grade 1 to 4000
Hypernatremia — Grade 2 to 0000
Hypernatremia — Grade 2 to 1000
Hypernatremia — Grade 2 to 2000
Hypernatremia — Grade 2 to 3000
Hypernatremia — Grade 2 to 4000
Hypernatremia — Grade 3 to 0000
Hypernatremia — Grade 3 to 1000
Hypernatremia — Grade 3 to 2000
Hypernatremia — Grade 3 to 3000
Hypernatremia — Grade 3 to 4000
Hypernatremia — Grade 4 to 0000
Hypernatremia — Grade 4 to 1000
Hypernatremia — Grade 4 to 2000
Hypernatremia — Grade 4 to 3000
Hypernatremia — Grade 4 to 4000
Hypoalbuminemia — Grade 0 to 0124
Hypoalbuminemia — Grade 0 to 1101
Hypoalbuminemia — Grade 0 to 2102
Hypoalbuminemia — Grade 0 to 3000
Hypoalbuminemia — Grade 0 to 4NANANA
Hypoalbuminemia — Grade 1 to 0000
Hypoalbuminemia — Grade 1 to 1000
Hypoalbuminemia — Grade 1 to 2000
Hypoalbuminemia — Grade 1 to 3000
Hypoalbuminemia — Grade 1 to 4NANANA
Hypoalbuminemia — Grade 2 to 0000
Hypoalbuminemia — Grade 2 to 1000
Hypoalbuminemia — Grade 2 to 2000
Hypoalbuminemia — Grade 2 to 3000
Hypoalbuminemia — Grade 2 to 4NANANA
Hypoalbuminemia — Grade 3 to 0000
Hypoalbuminemia — Grade 3 to 1000
Hypoalbuminemia — Grade 3 to 2000
Hypoalbuminemia — Grade 3 to 3000
Hypoalbuminemia — Grade 3 to 4NANANA
Hypoalbuminemia — Grade 4 to 0NANANA
Hypoalbuminemia — Grade 4 to 1NANANA
Hypoalbuminemia — Grade 4 to 2NANANA
Hypoalbuminemia — Grade 4 to 3NANANA
Hypoalbuminemia — Grade 4 to 4NANANA
Hypocalcemia — Grade 0 to 0226
Hypocalcemia — Grade 0 to 1100
Hypocalcemia — Grade 0 to 2000
Hypocalcemia — Grade 0 to 3000
Hypocalcemia — Grade 0 to 4000
Hypocalcemia — Grade 1 to 0000
Hypocalcemia — Grade 1 to 1001
Hypocalcemia — Grade 1 to 2000
Hypocalcemia — Grade 1 to 3000
Hypocalcemia — Grade 1 to 4000
Hypocalcemia — Grade 2 to 0000
Hypocalcemia — Grade 2 to 1000
Hypocalcemia — Grade 2 to 2000
Hypocalcemia — Grade 2 to 3000
Hypocalcemia — Grade 2 to 4000
Hypocalcemia — Grade 3 to 0000
Hypocalcemia — Grade 3 to 1000
Hypocalcemia — Grade 3 to 2000
Hypocalcemia — Grade 3 to 3000
Hypocalcemia — Grade 3 to 4000
Hypocalcemia — Grade 4 to 0000
Hypocalcemia — Grade 4 to 1000
Hypocalcemia — Grade 4 to 2000
Hypocalcemia — Grade 4 to 3000
Hypocalcemia — Grade 4 to 4000
Hypoglycemia — Grade 0 to 0327
Hypoglycemia — Grade 0 to 1000
Hypoglycemia — Grade 0 to 2000
Hypoglycemia — Grade 0 to 3000
Hypoglycemia — Grade 0 to 4000
Hypoglycemia — Grade 1 to 0000
Hypoglycemia — Grade 1 to 1000
Hypoglycemia — Grade 1 to 2000
Hypoglycemia — Grade 1 to 3000
Hypoglycemia — Grade 1 to 4000
Hypoglycemia — Grade 2 to 0000
Hypoglycemia — Grade 2 to 1000
Hypoglycemia — Grade 2 to 2000
Hypoglycemia — Grade 2 to 3000
Hypoglycemia — Grade 2 to 4000
Hypoglycemia — Grade 3 to 0000
Hypoglycemia — Grade 3 to 1000
Hypoglycemia — Grade 3 to 2000
Hypoglycemia — Grade 3 to 3000
Hypoglycemia — Grade 3 to 4000
Hypoglycemia — Grade 4 to 0000
Hypoglycemia — Grade 4 to 1000
Hypoglycemia — Grade 4 to 2000
Hypoglycemia — Grade 4 to 3000
Hypoglycemia — Grade 4 to 4000
Hypokalemia — Grade 0 to 0214
Hypokalemia — Grade 0 to 1NANANA
Hypokalemia — Grade 0 to 2012
Hypokalemia — Grade 0 to 3100
Hypokalemia — Grade 0 to 4000
Hypokalemia — Grade 1 to 0NANANA
Hypokalemia — Grade 1 to 1NANANA
Hypokalemia — Grade 1 to 2NANANA
Hypokalemia — Grade 1 to 3NANANA
Hypokalemia — Grade 1 to 4NANANA
Hypokalemia — Grade 2 to 0000
Hypokalemia — Grade 2 to 1NANANA
Hypokalemia — Grade 2 to 2001
Hypokalemia — Grade 2 to 3000
Hypokalemia — Grade 2 to 4000
Hypokalemia — Grade 3 to 0000
Hypokalemia — Grade 3 to 1NANANA
Hypokalemia — Grade 3 to 2000
Hypokalemia — Grade 3 to 3000
Hypokalemia — Grade 3 to 4000
Hypokalemia — Grade 4 to 0000
Hypokalemia — Grade 4 to 1NANANA
Hypokalemia — Grade 4 to 2000
Hypokalemia — Grade 4 to 3000
Hypokalemia — Grade 4 to 4000
Hypomagnesemia — Grade 0 to 0223
Hypomagnesemia — Grade 0 to 1004
Hypomagnesemia — Grade 0 to 2100
Hypomagnesemia — Grade 0 to 3000
Hypomagnesemia — Grade 0 to 4000
Hypomagnesemia — Grade 1 to 0000
Hypomagnesemia — Grade 1 to 1000
Hypomagnesemia — Grade 1 to 2000
Hypomagnesemia — Grade 1 to 3000
Hypomagnesemia — Grade 1 to 4000
Hypomagnesemia — Grade 2 to 0000
Hypomagnesemia — Grade 2 to 1000
Hypomagnesemia — Grade 2 to 2000
Hypomagnesemia — Grade 2 to 3000
Hypomagnesemia — Grade 2 to 4000
Hypomagnesemia — Grade 3 to 0000
Hypomagnesemia — Grade 3 to 1000
Hypomagnesemia — Grade 3 to 2000
Hypomagnesemia — Grade 3 to 3000
Hypomagnesemia — Grade 3 to 4000
Hypomagnesemia — Grade 4 to 0000
Hypomagnesemia — Grade 4 to 1000
Hypomagnesemia — Grade 4 to 2000
Hypomagnesemia — Grade 4 to 3000
Hypomagnesemia — Grade 4 to 4000
Hyponatremia — Grade 0 to 0214
Hyponatremia — Grade 0 to 1100
Hyponatremia — Grade 0 to 2NANANA
Hyponatremia — Grade 0 to 3003
Hyponatremia — Grade 0 to 4000
Hyponatremia — Grade 1 to 0000
Hyponatremia — Grade 1 to 1000
Hyponatremia — Grade 1 to 2NANANA
Hyponatremia — Grade 1 to 3010
Hyponatremia — Grade 1 to 4000
Hyponatremia — Grade 2 to 0NANANA
Hyponatremia — Grade 2 to 1NANANA
Hyponatremia — Grade 2 to 2NANANA
Hyponatremia — Grade 2 to 3NANANA
Hyponatremia — Grade 2 to 4NANANA
Hyponatremia — Grade 3 to 0000
Hyponatremia — Grade 3 to 1000
Hyponatremia — Grade 3 to 2NANANA
Hyponatremia — Grade 3 to 3000
Hyponatremia — Grade 3 to 4000
Hyponatremia — Grade 4 to 0000
Hyponatremia — Grade 4 to 1000
Hyponatremia — Grade 4 to 2NANANA
Hyponatremia — Grade 4 to 3000
Hyponatremia — Grade 4 to 4000
Lipase increased — Grade 0 to 0125
Lipase increased — Grade 0 to 1200
Lipase increased — Grade 0 to 2001
Lipase increased — Grade 0 to 3001
Lipase increased — Grade 0 to 4000
Lipase increased — Grade 1 to 0000
Lipase increased — Grade 1 to 1000
Lipase increased — Grade 1 to 2000
Lipase increased — Grade 1 to 3000
Lipase increased — Grade 1 to 4000
Lipase increased — Grade 2 to 0000
Lipase increased — Grade 2 to 1000
Lipase increased — Grade 2 to 2000
Lipase increased — Grade 2 to 3000
Lipase increased — Grade 2 to 4000
Lipase increased — Grade 3 to 0000
Lipase increased — Grade 3 to 1000
Lipase increased — Grade 3 to 2000
Lipase increased — Grade 3 to 3000
Lipase increased — Grade 3 to 4000
Lipase increased — Grade 4 to 0000
Lipase increased — Grade 4 to 1000
Lipase increased — Grade 4 to 2000
Lipase increased — Grade 4 to 3000
Lipase increased — Grade 4 to 4000
Serum amylase increased — Grade 0 to 0224
Serum amylase increased — Grade 0 to 1101
Serum amylase increased — Grade 0 to 2000
Serum amylase increased — Grade 0 to 3000
Serum amylase increased — Grade 0 to 4000
Serum amylase increased — Grade 1 to 0000
Serum amylase increased — Grade 1 to 1000
Serum amylase increased — Grade 1 to 2000
Serum amylase increased — Grade 1 to 3000
Serum amylase increased — Grade 1 to 4000
Serum amylase increased — Grade 2 to 0000
Serum amylase increased — Grade 2 to 1000
Serum amylase increased — Grade 2 to 2001
Serum amylase increased — Grade 2 to 3001
Serum amylase increased — Grade 2 to 4000
Serum amylase increased — Grade 3 to 0000
Serum amylase increased — Grade 3 to 1000
Serum amylase increased — Grade 3 to 2000
Serum amylase increased — Grade 3 to 3000
Serum amylase increased — Grade 3 to 4000
Serum amylase increased — Grade 4 to 0000
Serum amylase increased — Grade 4 to 1000
Serum amylase increased — Grade 4 to 2000
Serum amylase increased — Grade 4 to 3000
Serum amylase increased — Grade 4 to 4000
SecondaryPhase 1b of Sub-Study B: Objective Response Rate

ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months)
Reported as:
Number · Percentage of participants
Phase 1b of Sub-Study B: Objective Response Rate
Percentage of participantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Phase 1b of Sub-Study B: Objective Response Rate0.0 (0.0 to 70.8)0.0 (0.0 to 45.9)
SecondaryPhase 1b of Sub-Study B: Duration of Response (DR)

DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study B: Time to Tumor Response (TTR)

TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

Time frame:
From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)

No measurements were reported for this outcome.

SecondaryPhase 1b of Sub-Study B: Progression-Free Survival (PFS)

PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Reported as:
Median · Months
Phase 1b of Sub-Study B: Progression-Free Survival (PFS)
MonthsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Phase 1b of Sub-Study B: Progression-Free Survival (PFS)3.6 (0.7 to NA)6.5 (3.6 to NA)
SecondaryPhase 2 of Sub-Study B: Duration of Response (DR)

DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
Reported as:
Median · Months
Phase 2 of Sub-Study B: Duration of Response (DR)
MonthsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 of Sub-Study B: Duration of Response (DR)NA (NA to NA)NA (NA to NA)5.8 (NA to NA)
SecondaryPhase 2 of Sub-Study B: Time to Tumor Response (TTR)

TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.

Time frame:
From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
Reported as:
Median · Months
Phase 2 of Sub-Study B: Time to Tumor Response (TTR)
MonthsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 of Sub-Study B: Time to Tumor Response (TTR)4.1 (4.1 to 4.1)1.3 (1.3 to 1.3)1.4 (1.4 to 1.4)
SecondaryPhase 2 of Sub-Study B: Progression-Free Survival (PFS)

PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Reported as:
Median · Months
Phase 2 of Sub-Study B: Progression-Free Survival (PFS)
MonthsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 of Sub-Study B: Progression-Free Survival (PFS)4.2 (4.0 to NA)NA (2.8 to NA)3.4 (1.4 to NA)
SecondaryPhase 2 of Sub-Study B: Overall Survival (OS)

OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.

Time frame:
From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months)
Reported as:
Median · Months
Phase 2 of Sub-Study B: Overall Survival (OS)
MonthsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 of Sub-Study B: Overall Survival (OS)NA (NA to NA)NA (NA to NA)4.0 (NA to NA)
SecondaryPhase 1b of Sub-Study B: Cmax of Sasanlimab
Time frame:
Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Cmax of Sasanlimab
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 18840 ± 12711570 ± 79
Cycle 523080 ± NA47340 ± 42
SecondaryPhase 1b of Sub-Study B: Cmax of Axitinib
Time frame:
Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Cmax of Axitinib
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 1 Day 15.094 ± NA22.81 ± 80
Cycle 1 Day 83.440 ± NA13.74 ± 106
Cycle 5 Day 1—33.79 ± 73
Cycle 5 Day 813.10 ± NA24.85 ± NA
SecondaryPhase 1b of Sub-Study B: Cmax of SEA-TGT
Time frame:
Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Cmax of SEA-TGT
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 142550 ± 109
Cycle 532660 ± 17
SecondaryPhase 2 of Sub-Study B: Cmax of Sasanlimab
Time frame:
Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Cmax of Sasanlimab
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 111780 ± 4513810 ± NA10350 ± 45
Cycle 5—43500 ± NA20600 ± NA
SecondaryPhase 2 of Sub-Study B: Cmax of Axitinib
Time frame:
Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Cmax of Axitinib
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 1 Day 137.43 ± 8518.23 ± NA11.18 ± 112
Cycle 1 Day 839.50 ± NA2.360 ± NA2.708 ± 132
Cycle 5 Day 1—11.10 ± NA7.710 ± NA
SecondaryPhase 2 of Sub-Study B: Cmax of SEA-TGT
Time frame:
Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Cmax of SEA-TGT
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 136970 ± 3635500 ± NA30590 ± 39
Cycle 5—43000 ± NA44900 ± NA
SecondaryPhase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame:
Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 523000 ± NA23170 ± 29
SecondaryPhase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame:
Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 1 Day 83.440 ± NA13.74 ± 106
Cycle 5 Day 1—29.42 ± NA
Cycle 5 Day 813.10 ± NA24.85 ± NA
SecondaryPhase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame:
Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Nanograms per milliliterPhase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
Cycle 54813 ± 35
SecondaryPhase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame:
Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 1——87.01 ± NA
Cycle 5—30400 ± NA20000 ± NA
SecondaryPhase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame:
Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 1 Day 839.50 ± NA2.360 ± NA2.708 ± 132
Cycle 5 Day 1——3.630 ± NA
SecondaryPhase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame:
Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Reported as:
Geometric mean · Nanograms per milliliter
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Nanograms per milliliterPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Cycle 1—55.00 ± NA24.47 ± NA
Cycle 5—5770 ± NA8490 ± NA
SecondaryPhase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT

A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

Time frame:
Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Reported as:
Count of participants · Participants
Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
ParticipantsPhase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)
ADA against sasanlimab01
ADA against SEA-TGT—0
SecondaryPhase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
Time frame:
Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Reported as:
Count of participants · Participants
Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
ParticipantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
ADA against sasanlimab000
ADA against SEA-TGT100
SecondaryPhase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue

ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.

Time frame:
From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Reported as:
Number · Percentage of participants
Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue
Percentage of participantsPhase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue33.3 (0.8 to 90.6)0 (0.0 to 84.2)14.3 (0.4 to 57.9)

Adverse events

Collected over From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)0/4 (0%)2/4 (50%)4/4 (100%)
Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)4/9 (44.4%)7/9 (77.8%)9/9 (100%)
Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)5/6 (83.3%)3/6 (50%)6/6 (100%)
Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)0/2 (0%)0/2 (0%)2/2 (100%)
Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)3/7 (42.9%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
EnteritisGastrointestinal disorders0/40/90/30/61/30/20/7
ColitisGastrointestinal disorders0/40/90/30/61/30/20/7
HypoglycaemiaMetabolism and nutrition disorders0/40/91/30/60/30/20/7
Acute kidney injuryRenal and urinary disorders0/40/90/30/61/30/20/7
DiverticulitisInfections and infestations1/40/90/30/60/30/20/7
Lower respiratory tract infectionInfections and infestations1/40/90/30/60/30/20/7
PneumoniaInfections and infestations1/40/90/31/60/30/21/7
Supraventricular tachycardiaCardiac disorders1/40/90/30/60/30/20/7
Ejection fraction decreasedInvestigations1/40/90/30/60/30/20/7
PyrexiaGeneral disorders0/42/90/30/60/30/20/7
Most frequent other events
Showing 10 of 168
Most frequent other events
EventPhase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)
Aspartate aminotransferase increasedInvestigations1/43/93/31/61/31/22/7
Infusion related reactionInjury, poisoning and procedural complications0/40/90/31/60/32/21/7
AnaemiaBlood and lymphatic system disorders0/43/92/32/62/30/20/7
Abdominal painGastrointestinal disorders0/41/92/30/61/30/21/7
ConstipationGastrointestinal disorders2/42/90/32/62/30/22/7
DiarrhoeaGastrointestinal disorders1/43/91/33/62/30/23/7
NauseaGastrointestinal disorders2/43/90/31/62/30/23/7
FatigueGeneral disorders1/44/92/33/62/31/23/7
Alanine aminotransferase increasedInvestigations1/44/92/31/61/31/22/7
Blood alkaline phosphatase increasedInvestigations1/41/91/31/62/31/20/7

Baseline characteristics

Full analysis set included all participants who received at least 1 dose of study drug. Participants were classified according to the treatment actually received.

Age, Categorical
Age, Categorical(Participants)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Total
<=18 years00000000
Between 18 and 65 years150110513
>=65 years343522221
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Total
Female331111212
Male162521522
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Total
Hispanic or Latino01000012
Not Hispanic or Latino483632632
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg)Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg)Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg)Total
American Indian or Alaska Native00000000
Asian15010007
Native Hawaiian or Other Pacific Islander00000000
Black or African American10021004
White243322723
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

55 sites
  • City of Hope Investigational Drug Services (IDS)
    Duarte, California 91010, United States
  • City of Hope
    Duarte, California 91010, United States
  • UCSD Medical Center - Encinitas
    Encinitas, California 92024, United States
  • California Cancer Associates for Research and Excellence, Inc (cCARE)
    Fresno, California 93720, United States
  • The Oncology Institute of Hope and Innovation
    Glendale, California 91204, United States
  • Koman Family Outpatient Pavilion
    La Jolla, California 92037, United States
  • Sulpizio Cardiovascular Center at UC San Diego Health
    La Jolla, California 92037, United States
  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
    La Jolla, California 92037, United States
  • UC San Diego Moores Cancer Center - Investigational Drug Services
    La Jolla, California 92037, United States
  • UCSD Perlman Medical Offices
    La Jolla, California 92037, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • The Oncology Institute of Hope and Innovation
    Long Beach, California 90805, United States
  • The Oncology Institute of Hope and Innovation
    Los Angeles, California 90015, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UC San Diego Medical Center - Hillcrest
    San Diego, California 92103, United States
  • The Oncology Institute of Hope and Innovation
    Santa Ana, California 92705, United States
  • UCSD Medical Center - Vista
    Vista, California 92081, United States
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90602, United States
  • AdventHealth Celebration Infusion Center
    Celebration, Florida 34747, United States
  • AdventHealth Medical Group Oncology Research at Celebration
    Celebration, Florida 34747, United States
  • Advent Health Orlando - Investigational Drug Services
    Orlando, Florida 32804, United States
  • AdventHealth Orlando Infusion Center
    Orlando, Florida 32804, United States
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Henry Ford Medical Center - Fairlane
    Dearborn, Michigan 48126, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Henry Ford Medical Center - Columbus
    Novi, Michigan 48377, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Mount Sinai Hospital Pharmacy
    New York, New York 10029, United States
  • Tennessee Oncology PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology PLLC
    Gallatin, Tennessee 37066, United States
  • Tennessee Oncology PLLC
    Hendersonville, Tennessee 37075, United States
  • Tennessee Oncology PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology PLLC
    Lebanon, Tennessee 37090, United States
  • Tennessee Oncology PLLC
    Murfreesboro, Tennessee 37129, United States
  • Sarah Cannon Research Institute - Pharmacy
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37205, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37211, United States
  • Tennessee Oncology PLLC
    Shelbyville, Tennessee 37160, United States
  • Tennessee Oncology PLLC
    Smyrna, Tennessee 37167, United States
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • Concord Hospital
    Concord, New South Wales 2139, Australia
  • GenesisCare North Shore
    St Leonards, New South Wales 2065, Australia
  • North Shore Radiology and Nuclear Medicine
    St Leonards, New South Wales 2065, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Antwerp University Hospital
    Edegem, Antwerpen 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Chung Shan Medical University Hospital
    Taichung, 40201, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Koo Foundation Sun Yat -Sen Cancer Center
    Taipei, 112, Taiwan
  • Koo Foundation Sun Yat-Sen Cancer Center
    Taipei, 112, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in May 2023, 30 months.

Results were first posted in Jun 2023, 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 14, 2020
StartActual
Nov 10, 2020
Primary completionActual
May 17, 2023
CompletionActual
Oct 29, 2024
Results first posted
Jun 22, 2023
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04585815
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Nov 10, 2020
Primary completion
May 17, 2023
Completion
Oct 29, 2024
Results posted
Jun 22, 2023
Last update
Jan 9, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Binimetinib · Sasanlimab

Start the discussion